Daniel L. Hertz, PharmD, PhD

[DLHertz@med.umich.edu](mailto:DLHertz@med.umich.edu)

|  |  |
| --- | --- |
| Present Position | Associate Professor  Department of Clinical Pharmacy  University of Michigan College of Pharmacy  428 Church Street  Ann Arbor, MI 48109  Office: (734) 763-0015  Fax: (734) 763-4480 |
| Education and Training | |
| **Sept 2008-**  **May 2013**  **Sept 2002-**  **May 2008** | University of North Carolina at Chapel Hill  UNC Eshelman School of Pharmacy  Division of Pharmacotherapy and Experimental Therapeutics  Chapel Hill, NC 27516  Degree: Doctor of Philosophy (PhD) May 2013  Rutgers, The State University of New Jersey  Ernest Mario School of Pharmacy  Piscataway, NJ 08854  Degree: Doctor of Pharmacy (PharmD) May 2008 (Summa Cum Laude) |
| Licensure | New Jersey (License #28RI03227100, Active)  North Carolina (License #20495, Inactive) |
| Professional Experience and academic appointments | |
| September 2023-Present  April 2016-  Present  Feb 2014-  present  April 2013-  April 2016 | Associate Professor  Department of Clinical Pharmacy  University of Michigan College of Pharmacy  Ann Arbor, Michigan  Assistant Professor  Department of Clinical Pharmacy  University of Michigan College of Pharmacy  Ann Arbor, Michigan  Core Member  University of Michigan Rogel Cancer Center  Ann Arbor, Michigan  Research Assistant Professor  Department of Clinical Pharmacy  University of Michigan College of Pharmacy  Ann Arbor, Michigan |
| Publications Peer-reviewed Publications:  1. Chan RJ. Knowles R, Ashbury FD, Bowen J, Chan A, Chin M, Oliver I, Taylor C, Tinianov S, Alberti P, Bossi P, Brito-Dellan N, Cooksley T, Crawford GB, Dixit N, Fitch MI, Freedman JL, Ginex PK, Hart NH, **Hertz DL**, Jefford M, Boczwara B, Naito T, Orsey AD, Ruhlmann CH, Tsoukalas N, va den Hurk Co, Van Sebille Y, Wardill HR, Scotte F, Lustberg ML. Supportive Care 2030 Movement: Towards Unifying Ambitions for Global Excellence in Supportive Cancer Care. eClinicalMedicine (The Lancet).   Role: Critical Review   1. Wang C, Hwang M\*, Paulson B\*, Mhandire D, Ozair S, O’Connor T, Gandhi S, Attwood KM, **Hertz DL**, Goey AKL. Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity. Pharmacogenomics 2024   Role: Conceptualization, Analysis Design, Critical Review   1. Tracksdorf T, Pearse S, Smith DM, Scott SA, Ho TT, Aquilante CL, Patel JN, Cicali EJ, Hicks JK, **Hertz DL**. Strategies for DPYD Testing Prior to Fluoropyrimidine Chemotherapy in the United States. Supportive Care in Cancer.   Role: Conceptualization, Critical Review, Corresponding Author   1. Chen CS\*\*, Zirpoli G, Budd GT, Barlow WE, Pusztai L, Hortobagyi GN, Albain KS, Godwin AK, Thompson A, Henry NL, Ambrosone CB, Stringer KA, **Hertz DL.** Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221. Cancer Chemotherapy and Pharmacology   Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author   1. **Hertz DL**, Joerger M, Bang YJ, Mathijssen RH, Zhou C, Zhang L, Gandara D, Stahl M, Monk BJ, Jaehde U Beumer JH. [Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations.](https://www.ncbi.nlm.nih.gov/pubmed/38513383/)Eur J Cancer. 2024 May;202:114024. doi: 10.1016/j.ejca.2024.114024. Epub 2024 Mar 19. Review. PubMed PMID: 38513383; PubMed Central PMCID: PMC11053297.   Role: Data Collection, Writing, Critical Review   1. Mc Laughlin AM, Helland T^, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar HJ, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, **Hertz DL**, On behalf of the CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium. [Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort.](https://www.ncbi.nlm.nih.gov/pubmed/38494911/)Clin Pharmacol Ther. 2024 Mar 18;. doi: 10.1002/cpt.3238. [Epub ahead of print] PubMed PMID: 38494911.   Role: Conceptualization, Data Collection, Writing, Corresponding Author   1. Patel JN, Jiang C, Owzar K, **Hertz DL**, Mulkey FA, Kelly WK, Halabi S, Furukawa Y, Lassiter C, Dorsey SG, Friedman PN, Small EJ, Febbo PG, Kroetz DL, Carducci MA, Mahoney JF, Kelley MJ, Nakamura Y, Kubo M, Ratain MJ, Morris MJ, McLeod HL. [Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance).](https://www.ncbi.nlm.nih.gov/pubmed/38438359/)Pharmacogenomics J. 2024 Mar 4;24(2):6. doi: 10.1038/s41397-024-00328-z. PubMed PMID: 38438359; PubMed Central PMCID: PMC10912014.   Role: Data Collection, Critical Review   1. Rattsev I, Stearns V, Blackford AL, **Hertz DL**, Smith KL, Rae JM, Taylor CO. [Incorporation of emergent symptoms and genetic covariates improves prediction of aromatase inhibitor therapy discontinuation.](https://www.ncbi.nlm.nih.gov/pubmed/38250582/)JAMIA Open. 2024 Apr;7(1):ooae006. doi: 10.1093/jamiaopen/ooae006. eCollection 2024 Apr. PubMed PMID: 38250582; PubMed Central PMCID: PMC10799747.   Role: Critical Review   1. Liang Y\*, Gersch CL, Lehman J, Henry NL, Smith KL, Rae JM, Stearns V, **Hertz DL**. [Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms.](https://www.ncbi.nlm.nih.gov/pubmed/38359166/)Pharmacogenet Genomics. 2024 Jun 1;34(4):126-129. doi: 10.1097/FPC.0000000000000522. Epub 2024 Feb 8. PubMed PMID: 38359166.   Role: Conceptualization, Critical Review, Corresponding Author   1. Granados J^^, Pasternak AL, Henry NL, Sahai V, **Hertz DL.** [Risk of Toxicity From Topical 5-Fluorouracil Treatment in Patients Carrying DPYD Variant Alleles.](https://www.ncbi.nlm.nih.gov/pubmed/38060335/)Clin Pharmacol Ther. 2024 Mar;115(3):452-456. doi: 10.1002/cpt.3131. Epub 2023 Dec 18. PubMed PMID: 38060335; PubMed Central PMCID: PMC10947784.   Role: Conceptualization, Writing, Corresponding Author   1. **Hertz DL**, Tofthagen C, Rossi E, Bernasconi DP, Lim J, Carlson M, Sheffield KE, Nekhlyudov L, Grech L, Von Ah D, Mayo SJ, Ruddy KJ, Chan A, Alberti P, Lustberg MB, Tanay M. [Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy.](https://www.ncbi.nlm.nih.gov/pubmed/38129602/)Support Care Cancer. 2023 Dec 22;32(1):48. doi: 10.1007/s00520-023-08209-0. PubMed PMID: 38129602.   Role: Conceptualization, Writing, Corresponding Author   1. Rutherford DV, Medley S, Henderson NC, Gersch CL, Vandenberg TA, Albain KS, Dakhil SR, Tirumali NR, Gralow J, Hortobagyi GN, Pusztai L, Mehta RS, Hayes DF, Kidwell KM, Henry NL, Barlow WE, Rae JM, **Hertz DL**. [Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226.](https://www.ncbi.nlm.nih.gov/pubmed/37615099/)Pharmacogenomics. 2023 Aug;24(12):665-673. doi: 10.2217/pgs-2023-0097. Epub 2023 Aug 24. PubMed PMID: 37615099; PubMed Central PMCID: PMC10565537.   Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author   1. Chen CS\*\*, Zirpoli G, Barlow WE, Budd GT, McKiver B, Pusztai L, Hortobagyi GN, Albain KS, Damaj MI, Godwin AK, Thompson A, Henry NL, Ambrosone CB, Stringer KA, **Hertz DL**.  [Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.](https://www.ncbi.nlm.nih.gov/pubmed/37935109/)J Natl Compr Canc Netw. 2023 Nov;21(11):1172-1180.e3. doi: 10.6004/jnccn.2023.7062. PubMed PMID: 37935109; PubMed Central PMCID: PMC10976748.   Selected by JNCCN Editorial Board to be highlighted in Press Release  Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author   1. Pasternak AL, Seda R, Lipa J, McDevitt RL, Crysler OV, Swiecki P, Schneider B, Vanderwerff B, Henry NL, Krauss JC, Sahai V, **Hertz DL**. [Confirmatory *DPYD* Testing in Patients Receiving Fluoropyrimidines Who are Suspected *DPYD* Variant Carriers Based on a Genetic Data Repository.](https://www.ncbi.nlm.nih.gov/pubmed/37163252/)Clin Pharmacol Ther. 2023 Aug;114(2):356-361. doi: 10.1002/cpt.2936. Epub 2023 May 30. PubMed PMID: 37163252.   Role: Conceptualization, Writing, Corresponding Author   1. **Hertz DL**, Douglas JA, Miller RM, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. [Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms.](https://www.ncbi.nlm.nih.gov/pubmed/35776183/)Support Care Cancer. 2022 Jul 1;. doi: 10.1007/s00520-022-07243-8. [Epub ahead of print] PubMed PMID: 35776183.   Role: Conceptualization, Writing, Corresponding Author   1. Chen CS\*\*, Lavoie Smith EM, Stringer KA, Henry NL, **Hertz DL**. [Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel.](https://www.ncbi.nlm.nih.gov/pubmed/35760975/)Breast Cancer Res Treat. 2022 Jun 28;. doi: 10.1007/s10549-022-06652-x. [Epub ahead of print] PubMed PMID: 35760975.   Role: Conceptualization, Critical Review, Corresponding Author   1. Hwang M\*, Medley S, Shakeel F^, Vanderwerff B, Zawistowski M, Kidwell KM, **Hertz DL**. [Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer.](https://www.ncbi.nlm.nih.gov/pubmed/35606478/)Support Care Cancer. 2022 May 24;. doi: 10.1007/s00520-022-07118-y. [Epub ahead of print] PubMed PMID: 35606478.   Role: Conceptualization, Critical Review, Corresponding Author   1. Koo K\*, Pasternak AL, Henry NL, Sahai V, **Hertz DL.** [Survey of US Medical Oncologists' Practices and Beliefs Regarding *DPYD* Testing Before Fluoropyrimidine Chemotherapy.](https://www.ncbi.nlm.nih.gov/pubmed/35239419/)JCO Oncol Pract. 2022 Jun;18(6):e958-e965. doi: 10.1200/OP.21.00874. Epub 2022 Mar 3. PubMed PMID: 35239419.   Role: Conceptualization, Analysis Design, Data Collection, Critical Review, Corresponding Author   1. **Hertz DL**, Chen L\*, Henry NL, Griggs JJ, Hayes DF, Derstine BA, Su GL, Wang SC, Pai MP, [Muscle mass affects paclitaxel systemic exposure and may inform personalized paclitaxel dosing.](https://www.ncbi.nlm.nih.gov/pubmed/35083783/)Br J Clin Pharmacol. 2022 Jan 26;. doi: 10.1111/bcp.15244. [Epub ahead of print] PubMed PMID: 35083783.   Role: Conceptualization, Analysis Design, Writing, Corresponding Author   1. Schumacher L, Fang F, Kidwell KM, Shakeel F^, **Hertz DL**, Park JM, Pasternak AL. [SLCO1B3 polymorphisms and clinical outcomes in kidney transplant recipients receiving mycophenolate.](https://www.ncbi.nlm.nih.gov/pubmed/34612072/)Pharmacogenomics. 2021 Nov;22(17):1111-1120. doi: 10.2217/pgs-2021-0102. Epub 2021 Oct 6. PubMed PMID: 34612072.   Role: Conceptualization, Critical Review   1. Pasternak AL^, Marcath LA^, Li Y, Ngyuen M\*, Gersch CL, Rae JM, Frame D, Scappaticci G, Kidwell KM, **Hertz DL**. [Impact of Pharmacogenetics on Intravenous Tacrolimus Exposure and Conversions to Oral Therapy.](https://www.ncbi.nlm.nih.gov/pubmed/34583027/)Transplant Cell Ther. 2022 Jan;28(1):19.e1-19.e7. doi: 10.1016/j.jtct.2021.09.011. Epub 2021 Sep 25. PubMed PMID: 34583027.   Role: Conceptualization, Critical Review   1. Quintanilha JCF, Wang J, Jiang C, Sibley AB, Etheridge AS, Shen F, Mulkey F, Patel JN, **Hertz DL**, Ratain MJ, Kroetz DL, Dees ED, Owzar K, McLeod HL, Rugo H, Kindler HL, Kelly WK, Schneider B, Lin D, Innocenti F [Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.](https://www.ncbi.nlm.nih.gov/pubmed/34616010/)Br J Cancer. 2022 Feb;126(2):265-274. doi: 10.1038/s41416-021-01557-w. Epub 2021 Oct 6. PubMed PMID: 34616010; PubMed Central PMCID: PMC8770703.   Role: Data Collection, Critical Review   1. Chen CS\*\*, Kim J\*, Garg N^^, Guntupalli H\*, Jagsi R, Griggs JJ, Sabel M, Dorsch MP, Callaghan B, **Hertz DL**. [Chemotherapy-Induced Peripheral Neuropathy Detection via a Smartphone App: Cross-sectional Pilot Study.](https://www.ncbi.nlm.nih.gov/pubmed/36260403/) 2021 Jul 5;9(7):e27502. doi: 10.2196/27502. PubMed PMID: 36260403; PubMed Central PMCID: PMC8406129.   Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author   1. Chen Y^^, Marcath LA^, Eliassen FM, Lende TH, Søiland H, Mellgren G, Helland T^, **Hertz DL**. [Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites.](https://www.ncbi.nlm.nih.gov/pubmed/34199712/)J Pers Med. 2021 Jun 4;11(6). doi: 10.3390/jpm11060507. PubMed PMID: 34199712; PubMed Central PMCID: PMC8228634.   Role: Conceptualization, Critical Review, Corresponding Author   1. **Hertz DL,** Smith KL, Zong Y, Gersch CL, Pesch AM, Lehman J, Blackford AL, Henry NL, Kidwell KM, Rae JM, Stearns V. [Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer.](https://www.ncbi.nlm.nih.gov/pubmed/34211496/)Front Genet. 2021;12:662734. doi: 10.3389/fgene.2021.662734. eCollection 2021. PubMed PMID: 34211496; PubMed Central PMCID: PMC8239354.   Role: Conceptualization, Writing, Corresponding Author   1. **Hertz DL**, Dockter TJ, Satele DV, Loprinzi CL, Le-Rademacher J,  [Neuropathy severity at the time of oxaliplatin treatment alteration in patients with colon cancer (Alliance A151912).](https://www.ncbi.nlm.nih.gov/pubmed/34176021/)Support Care Cancer. 2021 Jun 27;. doi: 10.1007/s00520-021-06371-x. [Epub ahead of print] PubMed PMID: 34176021.   Role: Conceptualization, Writing, Corresponding Author   1. Chen L\*, Chen CS\*\*, Sun Y, Henry NL, Stringer KA, **Hertz DL**. [Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability.](https://www.ncbi.nlm.nih.gov/pubmed/34089352/) Cancer Chemother Pharmacol. 2021 Jun 5;. doi: 10.1007/s00280-021-04300-7. [Epub ahead of print] PubMed PMID: 34089352   Role: Conceptualization, Critical Review, Corresponding Author   1. Shakeel F^, Fang F, Kwon JW\*, Koo K\*, Pasternak AL, Henry NL, Sahai V, Kidwell KM, **Hertz DL**. [Patients carrying *DPYD* variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy.](https://www.ncbi.nlm.nih.gov/pubmed/33410339/)Pharmacogenomics. 2021 Feb;22(3):145-155. doi: 10.2217/pgs-2020-0154. Epub 2021 Jan 7. PubMed PMID: 33410339.   Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author   1. Marcath LA^, Finley C\*, Wong SF, **Hertz DL.** [Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy.](https://www.ncbi.nlm.nih.gov/pubmed/33771105/)BMC Cancer. 2021 Mar 26;21(1):324. doi: 10.1186/s12885-021-08050-w. PubMed PMID: 33771105; PubMed Central PMCID: PMC7995697.   Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author   1. Van Poznak C, Reynolds EL, Estilo CL, Hu M, Schneider BP, **Hertz DL**, Gersch CL, Thibert J, Thomas D, Banerjee M, Rae JM, Hayes DF. [Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer.](https://www.ncbi.nlm.nih.gov/pubmed/33274559/)Oral Dis. 2020 Dec 4;. doi: 10.1111/odi.13746. [Epub ahead of print] PubMed PMID: 33274559.   Role: Analysis Design, Writing, Critical Review   1. Helland T^, Naume B, Hustad S, Bifulco E, Kvaløy JT, Sætersdal AB, Synnestvedt M, Lende TH, Gilje B, Mjaaland I, Weyde K, Blix ES, Wiedswang G, Borgen E, **Hertz DL**, Janssen EAM, Mellgren G, Søiland H. [Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen.](https://www.ncbi.nlm.nih.gov/pubmed/33252186/)Mol Oncol. 2021 Apr;15(4):957-967. doi: 10.1002/1878-0261.12865. Epub 2020 Dec 14. PubMed PMID: 33252186; PubMed Central PMCID: PMC8024735.   Role: Critical Review   1. Akhtari FS, Havener TM, **Hertz DL**, Ash J, Larson A, Carey LA, McLeod HL, Motsinger-Reif AA. [Race and smoking status associated with paclitaxel drug response in patient-derived lymphoblastoid cell lines.](https://www.ncbi.nlm.nih.gov/pubmed/32941389/)Pharmacogenet Genomics. 2021 Feb 1;31(2):48-52. doi: 10.1097/FPC.0000000000000419. PubMed PMID: 32941389.   Role: Data Collection, Critical Review   1. **Hertz DL,** Douglas JA, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. [Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity](https://journals.lww.com/jpharmacogenetics/Abstract/9000/Genome_wide_association_study_of_letrozole_plasma.99129.aspx). Pharmacogenet Genomics. 2021 Jul 1;31(5):116-123. doi: 10.1097/FPC.0000000000000429. PubMed PMID: 34096894; PubMed Central PMCID: PMC8185249   Role: Conceptualization, Analysis Design, Writing, Critical Review, Corresponding Author   1. Marcath LA^, Coe TD\*, Shakeel F^, Reynolds E, Bayuk M, Haas S, Redman BG, Wong SF, **Hertz DL.** [Improvement Initiative to Develop and Implement a Tool for Detecting Drug-Drug Interactions During Oncology Clinical Trial Enrollment Eligibility Screening.](https://www.ncbi.nlm.nih.gov/pubmed/33003175/)J Patient Saf. 2021 Jan 1;17(1):e28-e34. doi: 10.1097/PTS.0000000000000772. PubMed PMID: 33003175; PubMed Central PMCID: PMC7775319.   Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author   1. Chen Y^^, Fang F, Kidwell KM, Vangipuram K\*, Marcath LA^, Gersch CL, Rae JM, Hayes DF, Smith EM, Henry NL, Beutler AS, **Hertz DL**. [Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy.](https://www.ncbi.nlm.nih.gov/pubmed/32700628/)Pharmacogenomics. 2020 Aug;21(12):841-851. doi: 10.2217/pgs-2020-0053. Epub 2020 Jul 23. PubMed PMID: 32700628; PubMed Central PMCID: PMC7444626.   Role: Conceptualization, Analysis Design, Writing, Critical Review, Corresponding Author   1. Jennaro TS\*\*, Fang F, Kidwell KM, Smith EM, Vangipuram K\*, Burness M, Griggs JJ, Van Poznak C, Hayes DF, Henry NL, **Hertz DL**. [Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy.](https://www.ncbi.nlm.nih.gov/pubmed/32166478/) Breast Cancer Res Treat. 2020 Apr;180(3):707-714. doi: 10.1007/s10549-020-05584-8. Epub 2020 Mar 12. PubMed PMID: 32166478.   Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author   1. Salgado TM, Liu J, Reed HL\*, Quinn CS\*, Syverson JG\*, Le-Rademacher J, Lopez CL, Beutler AS, Loprinzi CL, Vangipuram K, Smith EML, Henry NL, Farris KB, **Hertz DL**. [Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study.](https://www.ncbi.nlm.nih.gov/pubmed/32193049/)Breast. 2020 Jun;51:21-28. doi: 10.1016/j.breast.2020.02.011. Epub 2020 Mar 3. PubMed PMID: 32193049; PubMed Central PMCID: PMC7198332.   Role: Conceptualization, Analysis Design, Critical Review   1. Shakeel F^, Fang F, Kidwell KM, Marcath LA^, **Hertz DL.** [Comparison of eight screening tools to detect interactions between herbal supplements and oncology agents.](https://www.ncbi.nlm.nih.gov/pubmed/32075508/)J Oncol Pharm Pract. 2020 Dec;26(8):1843-1849. doi: 10.1177/1078155220905009. Epub 2020 Feb 19. PubMed PMID: 32075508.   Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author   1. Salgado TM, Quinn CS\*, Krumbach EK\*, Wenceslao I, Gonzalez M, Reed HL\*, Syverson JG\*, Etz RS, Vangipuram K\*, Baker MR, Henry NL, Farris KB, **Hertz DL**. [Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study.](https://www.ncbi.nlm.nih.gov/pubmed/31897779/)Support Care Cancer. 2020 Sep;28(9):4163-4172. doi: 10.1007/s00520-019-05254-6. Epub 2020 Jan 2. PubMed PMID: 31897779.   Role: Conceptualization, Critical Review   1. Marcath LA^, Kidwell KM, Vangipuram K\*, Gersch CL, Rae JM, Burness ML, Griggs JJ, Van Poznak C, Hayes DF, Smith EML, Henry NL, Beutler AS, **Hertz DL**. [Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy.](https://www.ncbi.nlm.nih.gov/pubmed/31823378/)Br J Clin Pharmacol. 2020 May;86(5):880-890. doi: 10.1111/bcp.14192. Epub 2020 Feb 4. PubMed PMID: 31823378; PubMed Central PMCID: PMC7163383.   Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author   1. Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, Gammal RS, Relling MV, Scott SA, **Hertz DL**, Guchelaar HJ, Gaedigk A. [Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group.](https://www.ncbi.nlm.nih.gov/pubmed/31647186/)Clin Transl Sci. 2020 Jan;13(1):116-124. doi: 10.1111/cts.12692. Epub 2019 Oct 24. PubMed PMID: 31647186; PubMed Central PMCID: PMC6951851.   Role: Analysis, Writing, Critical Review   1. Pasternak AL^, Kidwell KM, Dempsey JM\*, Gersch CL, Pesch A, Sun Y^, Rae JM, **Hertz DL**, Park JM [Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant.](https://www.ncbi.nlm.nih.gov/pubmed/30983501) Pharmacogenomics. 2019 Apr;20(6):421-432. doi: 10.2217/pgs-2019-0002. Epub 2019 Apr 15. PubMed PMID: 30983501.   Role: Analysis Design, Critical Review   1. Dempsey JM\*, Kidwell KM, Gersch CL, Pesch AM, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM, **Hertz DL**. [Effects of *SLCO1B1* polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.](https://www.ncbi.nlm.nih.gov/pubmed/31190621/)Pharmacogenomics. 2019 Jun;20(8):571-580. doi: 10.2217/pgs-2019-0020. PubMed PMID: 31190621; PubMed Central PMCID: PMC6891932.   Role: Conceptualization, Analysis Design, Writing, Critical Review, Corresponding Author   1. Kamdem LK, Xi J, Clark BL, Gregory BJ, Kidwell KM, Storniolo AM, Stearns V, Hayes DF, Gersch CL, Rae JM, Henry NL, **Hertz DL**. [Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17\*2 gene deletion.](https://www.ncbi.nlm.nih.gov/pubmed/30747308) Breast Cancer Res Treat. 2019 Jun;175(2):297-303. doi: 10.1007/s10549-019-05158-3. Epub 2019 Feb 12. PubMed PMID: 30747308; PubMed Central PMCID: PMC6534458.   Role: Analysis Design, Writing, Critical Review   1. Marcath LA^, Coe TD, Hoylman EK, Redman BG, **Hertz DL**. [Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials.](https://www.ncbi.nlm.nih.gov/pubmed/30466416) BMC Cancer 2018 Nov 22;18(1):1155. doi: 10.1186/s12885-018-5076-0.   Role: Conceptualization, Critical Review, Corresponding Author   1. Marcath LA^, Kidwell KM, Robinson A, Vangipuram K, Burness ML, Griggs JJ, Van Poznak CV, Schott AF, Hayes DF, Henry NL, **Hertz DL**. [Patients carrying CYP2C8\*3 have shorter systemic paclitaxel exposure.](https://www.ncbi.nlm.nih.gov/pubmed/30520341) Pharmacogenomics. 2019 Jan;20(2):95-104. doi: 10.2217/pgs-2018-0162. Epub 2018 Dec 6. PMID: 30520341   Role: Conceptualization, Critical Review, Corresponding Author   1. Sun Y^, Kim JH, Vangipuram K\*, Hayes DF, Lavoie Smith EM, Yeomans L, Henry NL, Stringer KA, **Hertz DL**.  [Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy.](https://www.ncbi.nlm.nih.gov/pubmed/29946863) Breast Cancer Res Treat. 2018 Oct;171(3):657-666. doi: 10.1007/s10549-018-4862-3. Epub 2018 Jun 26. PubMed PMID: 29946863; PubMed Central PMCID: PMC6119501.   Role: Conceptualization, Critical Review, Corresponding Author   1. **Hertz DL**, Glatz A\*, Pasternak AL^, Lonigro RJ, Vats P, Wu YM, Anderson B, Rabban E, Mora E, Frank K, Robinson DR, Mody RJ, Chinnaiyan AM. [Integration of Germline Pharmacogenetics Into a Tumor Sequencing Program.](https://www.ncbi.nlm.nih.gov/pubmed/32832831/)JCO Precis Oncol. 2018;2. doi: 10.1200/po.18.00011. Epub 2018 Jul 23. PubMed PMID: 32832831; PubMed Central PMCID: PMC7434089.   Role: Conceptualization, Analysis Design, Analysis, Writing, Corresponding Author   1. Marcath LA^, Xi J, Hoylman EK, Kidwell KM, Kraft SL, **Hertz DL**. [Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics.](https://www.ncbi.nlm.nih.gov/pubmed/29787332) J Oncol Pract. 2018 Jun;14(6):e368-e374. doi: 10.1200/JOP.18.00086. Epub 2018 May 22. PubMed PMID: 29787332.   Role: Conceptualization, Critical Review, Corresponding Author   1. **Hertz DL**, Kidwell KM, Vangipuram K\*, Li F, Pai MP, Burness ML, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Smith EM, Henry NL. [Paclitaxel Plasma Concentration After the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy.](https://www.ncbi.nlm.nih.gov/pubmed/29703818) Clin Cancer Res. 2018 Aug 1;24(15):3602-3610. doi: 10.1158/1078-0432.CCR-18-0656. Epub 2018 Apr 27. PubMed PMID: 29703818; PubMed Central PMCID: PMC6386454.   Role: Conceptualization, Analysis Design, Writing, Corresponding Author   1. Dempsey JM\*, Xi J, Henry NL, Rae JM, **Hertz DL**. [Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer.](https://www.ncbi.nlm.nih.gov/pubmed/29212847) Physiol Genomics. 2018 Feb 1;50(2):98-99. doi: 10.1152/physiolgenomics.00085.2017. Epub 2017 Dec 8. PubMed PMID: 29212847; PubMed Central PMCID: PMC5867615.   Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author   1. **Hertz DL**, Siden R, Modlin J, Gabel LL, Wong SF. [Drug interaction screening in SWOG clinical trials.](https://www.ncbi.nlm.nih.gov/pubmed/29748299) Am J Health Syst Pharm. 2018 May 15;75(10):607-612. doi: 10.2146/ajhp170449. PubMed PMID: 29748299.   Role: Conceptualization, Analysis Design, Analysis, Writing, Corresponding Author   1. Marcath LA\*, Deal AM, Van Wieren E\*, Danko W\*, Walko CM, Ibrahim JG, Weck KE, Jones DR, Desta Z, McLeod HL, Carey LA, Irvin Jr. WJ, **Hertz DL**. [Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.](https://www.ncbi.nlm.nih.gov/pubmed/28877533). Pharmacogenet Genomics. 2017 Nov;27(11):402-409. doi: 10.1097/FPC.0000000000000311. PubMed PMID: 28877533; PubMed Central PMCID: PMC5659294.   Role: Conceptualization, Critical Review, Corresponding Author   1. **Hertz DL**, Kidwell KM, Hilsenbeck SG, Oesterreich S, Osborne CK, Philips S, Chenault C, Hartmaier RJ, Skaar TC, Sikora MJ, Rae JM.  [CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.](https://www.ncbi.nlm.nih.gov/pubmed/28730340) Breast Cancer Res Treat. 2017 Nov;166(1):277-287. doi: 10.1007/s10549-017-4400-8. Epub 2017 Jul 20. PubMed PMID: 28730340; PubMed Central PMCID: PMC6028015.   Role: Design, Analysis Design, Writing, Corresponding Author   1. **Hertz DL**, Speth KA, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. [Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.](https://www.ncbi.nlm.nih.gov/pubmed/28643023) Breast Cancer Res Treat. 2017 Oct;165(3):659-668. doi: 10.1007/s10549-017-4346-x. Epub 2017 Jun 22. PubMed PMID: 28643023; PubMed Central PMCID: PMC5709190.   Role: Conceptualization, Analysis Design, Writing, Corresponding Author   1. Dolan ME, El Charif O, Wheeler HE, Gamazon ER, Ardeshir-Rouhani-Fard S, Monahan P, Feldman DR, Hamilton R, Vaughn DJ, Beard C, Fung C, Fossa SD, **Hertz DL**, Mushiroda T, Kubo M, Einhorn LH, Cox N, Travis L. [Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.](https://www.ncbi.nlm.nih.gov/pubmed/28611204) Clin Cancer Res. 2017 Oct 1;23(19):5757-5768. doi: 10.1158/1078-0432.CCR-16-3224. Epub 2017 Jun 13. PubMed PMID: 28611204; PubMed Central PMCID: PMC5626588.   Role: Critical Review   1. Ahern TP, **Hertz DL**, Damkier P, Ejlertsen B, Hamilton-Dutoit SJ, Rae JM, Regan MM, Thompson AM, Lash TL, Cronin-Fenton DP. [Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.](https://www.ncbi.nlm.nih.gov/pubmed/27988492) Am J Epidemiol. 2017 Jan 15;185(2):75-85. doi: 10.1093/aje/kww178. Epub 2016 Dec 17. PubMed PMID: 27988492; PubMed Central PMCID: PMC5253974.   Role: Critical Review   1. Robarge JD, Desta Z, Nguyen AT, Li L, **Hertz D**, Rae JM, Hayes DF, Storniolo AM, Stearns V, Flockhart DA, Skaar TC, Henry NL. [Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.](https://www.ncbi.nlm.nih.gov/pubmed/27943008) Breast Cancer Res Treat. 2017 Feb;161(3):453-461. doi: 10.1007/s10549-016-4077-4. Epub 2016 Dec 9. PubMed PMID: 27943008; PubMed Central PMCID: PMC5429096.   Role: Critical Review   1. **Hertz DL**, Henry NL, Kidwell KM, Thomas D, Goddard A, Azzouz F, Speth K, Li L, Banerjee M, Thibert JN, Kleer CG, Stearns V, Hayes DF, Skaar TC, Rae JM. [ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.](https://www.ncbi.nlm.nih.gov/pubmed/27542969) Physiol Genomics. 2016 Sep 1;48(9):688-98. doi: 10.1152/physiolgenomics.00065.2016. Epub 2016 Aug 19. PubMed PMID: 27542969; PubMed Central PMCID: PMC5111879.   Role: Analysis Design, Writing, Corresponding Author   1. **Hertz DL**, Barlow WE, Kidwell KM, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Livingston RB, Gralow J, Hayes DF, Hortobagyi GN, Mehta RS, Rae JM. [Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.](https://www.ncbi.nlm.nih.gov/pubmed/26859101) Br J Clin Pharmacol. 2016 Jun;81(6):1134-41. doi: 10.1111/bcp.12904. Epub 2016 Apr 8. PubMed PMID: 26859101; PubMed Central PMCID: PMC4876171.   Role: Writing, Corresponding Author   1. **Hertz DL**, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens ST, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL. [Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.](https://www.ncbi.nlm.nih.gov/pubmed/27143689) Clin Cancer Res. 2016 Oct 1;22(19):4890-4900. doi: 10.1158/1078-0432.CCR-15-2823. Epub 2016 May 3. PubMed PMID: 27143689; PubMed Central PMCID: PMC5050068.   Role: Conceptualization, Analysis Design, Writing   1. **Hertz DL**, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. [Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.](https://www.ncbi.nlm.nih.gov/pubmed/27549341) Pharmacogenomics J. 2017 Dec;17(6):521-527. doi: 10.1038/tpj.2016.60. Epub 2016 Aug 23. PubMed PMID: 27549341; PubMed Central PMCID: PMC5323433.   Role: Conceptualization, Analysis Design, Writing, Corresponding Author   1. **Hertz DL**, Deal A, Ibrahim JG, Walko CM, Weck KE, Anderson S, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Graham M, Peppercorn JM, Jones DR, Desta Z, Flockhart DA, Evans JP, McLeod HL, Carey LA, Irvin Jr. WJ [Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.](https://www.ncbi.nlm.nih.gov/pubmed/27226358) Oncologist. 2016 Jul;21(7):795-803. doi: 10.1634/theoncologist.2015-0480. Epub 2016 May 25. PubMed PMID: 27226358; PubMed Central PMCID: PMC4943390.   Role: Analysis Design, Writing   1. **Hertz DL**, Caram MV, Kidwell KM, Thibert JN, Gersch CL, Seewald NJ, Smerage J, Rubenfire M, Henry NL, Cooney KA, Leja M, Griggs JJ, Rae JM. [Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.](https://www.ncbi.nlm.nih.gov/pubmed/26799497) Pharmacogenomics. 2016 Feb;17(3):231-40. doi: 10.2217/pgs.15.162. Epub 2016 Jan 22. PubMed PMID: 26799497; PubMed Central PMCID: PMC5558515.   Role: Analysis Design, Writing, Corresponding Author   1. **Hertz DL**, Kidwell KM, Thibert JN, Gersch C, Regan MM, Skaar TC, Henry NL, Hayes DF, Van Poznak CH, Rae JM. [Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses.](https://www.ncbi.nlm.nih.gov/pubmed/26276228) Molecular Oncology 2015 Nov;9(9):1868-76. doi: 10.1016/j.molonc.2015.07.002. Epub 2015 Jul 29. PMID: 26276228 PMCID: PMC4624024   Role: Analysis Design, Writing, Corresponding Author   1. Caram ME, Guo C, Leja M, Smerage J, Henry NL, Giacherio D, Rubenfire M, Schott A, Davis M, Hayes DF, Van Poznak C, Cooney KA, **Hertz DL**, Banerjee M, Griggs JJ. [Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer.](https://www.ncbi.nlm.nih.gov/pubmed/26050157) Breast Cancer Res Treat. 2015 Jul;152(1):163-172. doi: 10.1007/s10549-015-3454-8. Epub 2015 Jun 7. PubMed PMID: 26050157.   Role: Critical Review   1. **Hertz DL**, Snavely AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S, Weck KE, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Peppercorn JM, Evans JP, Jones DR, Desta Z, Flockhart DA, Carey LA, Irivin Jr. WJ, [In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.](https://www.ncbi.nlm.nih.gov/pubmed/25907378) Br J Clin Pharmacol. 2015 Nov;80(5):1122-30. doi: 10.1111/bcp.12665. PMID: 25907378 PMCID: PMC4631184   Role: Conceptualization, Analysis Design, Writing, Corresponding Author   1. Patel JN**,** Jiang C, **Hertz DL**, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, Small EJ, Carducci MA, Mahoney JF, Kelley MJ, Morris MJ, Kelly WK, McLeod HL. [Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).](https://www.ncbi.nlm.nih.gov/pubmed/25417775) Cancer 2014 Nov 21 doi: 10.1002/cncr.29169. PMID: 25417775 PMCID: PMC4368497   Role: Critical Review   1. **Hertz DL**, Roy S, Jack J, Motsinger-Reif AA, Drobish A, Clark LS, Carey LA, Dees EC, McLeod HL, [Genetic heterogeneity beyond CYP2C8\*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.](https://www.ncbi.nlm.nih.gov/pubmed/24706167) Breast Cancer Res Treat 2014;145(1);245-54. PMID: 24706167, PMCID: PMC4256153   Role: Conceptualization, Analysis Design, Writing, Corresponding Author   1. McWhinney-Glass S\*, Winham SJ\*, **Hertz DL**, Yen-Revollo J, Paul J, He Y, Brown R, Motsinger-Reif AA, and McLeod HL, [Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.](https://www.ncbi.nlm.nih.gov/pubmed/23963862) Clin Cancer Res 2013 Oct 15;19(20):5769-76 doi:10.1158/1078-0432.CCR-13.0774 PMID: 23963862, PMCID: PMC3798385   Role: Critical Review   1. **Hertz DL**, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC. [CYP2C8\*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel.](https://www.ncbi.nlm.nih.gov/pubmed/23413280) Ann Oncol. 2013 Jun;24(6):1472-8. PMID: 23413280, PMCID: PMC3660078   Role: Conceptualization, Analysis Design, Writing, Corresponding Author   1. **Hertz DL**, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC. [CYP2C8\*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.](https://www.ncbi.nlm.nih.gov/pubmed/22527101) Breast Cancer Res Treat. 2012 Jul;134(1):401-10. PMID: 22527101, PMCID: PMC3727245   Role: Analysis Design, Writing, Corresponding Author   1. **Hertz DL**, Walko CM, Bridges AS, Hull JH, Herendeen J, Rollins K, Watkins PB, Dees EC. [Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.](https://www.ncbi.nlm.nih.gov/pubmed/22680343) Br J Clin Pharmacol. 2012 Jul;74(1):197-200. PMID: 22680343, PMCID: PMC3394145   Role: Analysis Design, Writing, Corresponding Author peer-reviewed review articles:  1. Sun Y\*\*, Cheng Y^^, **Hertz DL**. Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicity. Cancer Chemotherapy and Pharmacology   Role: Conceptualization, Corresponding author   1. **Hertz DL** Bousman CA, McLeod HL, Monte AA, Voora D, Orlando LA, Crutchley RD, Brown B, Teeple W, Rogers S, Patel JN. [Recommendations for pharmacogenetic testing in clinical practice guidelines in the US.](https://www.ncbi.nlm.nih.gov/pubmed/38652504/)Am J Health Syst Pharm. 2024 Apr 23;. doi: 10.1093/ajhp/zxae110. [Epub ahead of print] PubMed PMID: 38652504.   Role: Conceptualization, Writing, Corresponding Author   1. **Hertz DL**, Smith DM, Scott SA, Patel JN, Hicks JK. [Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy.](https://www.ncbi.nlm.nih.gov/pubmed/37350752/)Clin Pharmacol Ther. 2023 Oct;114(4):768-779. doi: 10.1002/cpt.2978. Epub 2023 Jul 11. Review. PubMed PMID: 37350752.   Role: Conceptualization, Writing, Corresponding Author  \*Article selected as cover story with accompanying editorial   1. Mantovani E, Demrozi F, **Hertz DL**, Turetta C, Ferro O, Argyriou AA, Pravadelli G, Tamburin S. [Wearables, sensors, and smart devices for the detection and monitoring of chemotherapy-induced peripheral neurotoxicity: Systematic review and directions for future research.](https://www.ncbi.nlm.nih.gov/pubmed/36224713/)J Peripher Nerv Syst. 2022 Dec;27(4):238-258. doi: 10.1111/jns.12518. Epub 2022 Nov 1. Review. PubMed PMID: 36224713.   Role: Critical Review   1. Nthontho KC, Ndlovu AK, Sharma K, Kasvosve I, **Hertz DL**, Paganotti GM. [Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective.](https://www.ncbi.nlm.nih.gov/pubmed/35761855/)Pharmgenomics Pers Med. 2022;15:613-652. doi: 10.2147/PGPM.S308531. eCollection 2022. Review. PubMed PMID: 35761855; PubMed Central PMCID: PMC9233488.   Role: Critical Review   1. **Hertz DL**, Childs DS, Park SB, Faithfull S, Ke Y, Ali NT, McGlown SM, Chan A, Grech L, Loprinzi CL, Ruddy KJ, Lustberg M.  [Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN).](https://www.ncbi.nlm.nih.gov/pubmed/34174668/)Cancer Treat Rev. 2021 Jun 9;99:102241. doi: 10.1016/j.ctrv.2021.102241. [Epub ahead of print] Review. PubMed PMID: 34174668.   Role: Conceptualization, Writing, Corresponding Author   1. **Hertz DL**, Arwood MJ, Stocco G, Singh S, Karnes JH, Ramsey LB. [Planning and Conducting a Pharmacogenetics Association Study.](https://www.ncbi.nlm.nih.gov/pubmed/33880756/)Clin Pharmacol Ther. 2021 Apr 20;. doi: 10.1002/cpt.2270. [Epub ahead of print] PubMed PMID: 33880756.   Role: Conceptualization, Writing, Critical Review, Corresponding Author   1. Helland T^, Alsomairy S\*, Lin C\*, Søiland H, Mellgren G, **Hertz DL.** [Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer.](https://www.ncbi.nlm.nih.gov/pubmed/33805613/)J Pers Med. 2021 Mar 13;11(3). doi: 10.3390/jpm11030201. Review. PubMed PMID: 33805613; PubMed Central PMCID: PMC8000933.   Role: Conceptualization, Writing, Critical Review   1. **Hertz DL.** [Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships.](https://www.ncbi.nlm.nih.gov/pubmed/33401943/)Expert Opin Drug Metab Toxicol. 2021 Feb;17(2):227-239. doi: 10.1080/17425255.2021.1856367. Epub 2021 Jan 6. PubMed PMID: 33401943; PubMed Central PMCID: PMC7864890.   Role: Conceptualization, Writing, Corresponding Author   1. Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, **Hertz DL**, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL. [Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update.](https://www.ncbi.nlm.nih.gov/pubmed/32663120/) J Clin Oncol. 2020 Oct 1;38(28):3325-3348. doi: 10.1200/JCO.20.01399. Epub 2020 Jul 14. PubMed PMID: 32663120.   Role: Critical Review   1. Marcath LA^, Pasternak AL, **Hertz D**L. [Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications.](https://www.ncbi.nlm.nih.gov/pubmed/31616046/)Pharmacogenomics J. 2019 Dec;19(6):501-515. doi: 10.1038/s41397-019-0105-1. Epub 2019 Oct 15. Review. PubMed PMID: 31616046.   Role: Conceptualization, Critical Review, Corresponding Author   1. Chan A, **Hertz DL**, Morales M, Adams EJ, Gordon S Tan CJ, Staff NP, Kamath J, Oh J, Shinde S, Pon D, Dixit N; D'Olimpio J, Dumitrescu C, Gobbo M, Kober K, Mayo S, Pang L, Subbiah I, Beutler AS, Peters KB, Loprinzi C, Lustberg M. [Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.](https://www.ncbi.nlm.nih.gov/pubmed/31363906) Support Care Cancer. 2019 Oct;27(10):3729-3737. doi: 10.1007/s00520-019-04987-8. Epub 2019 Jul 30. Review. PubMed PMID: 31363906; PubMed Central PMCID: PMC6728179.   Role: Writing, Critical Review   1. Pasternak AL^, Zhang L, **Hertz DL.** [CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration.](https://www.ncbi.nlm.nih.gov/pubmed/29629825) Pharmacogenomics. 2018 Apr;19(6):563-576. doi: 10.2217/pgs-2018-0003. Epub 2018 Apr 9. PubMed PMID: 29629825.   Role: Critical Review   1. Pasternak AL^, Ward K, Luzum J, Ellingrod VL, **Hertz DL**. [Germline genetic variants with implications for disease risk and therapeutic outcomes.](https://www.ncbi.nlm.nih.gov/pubmed/28887371). Physiological Genomics. Physiol Genomics. 2017 Oct 1;49(10):567-581. doi: 10.1152/physiolgenomics.00035.2017. Epub 2017 Sep 8. Review. PubMed PMID: 28887371; PubMed Central PMCID: PMC5668651.   Role: Conceptualization, Writing, Critical Review, Corresponding Author   1. **Hertz DL**, Henry NL, Rae JM. [Germline Genetic Predictors of AI Concentrations, Estrogen Suppression and Drug Efficacy and Toxicity in Breast Cancer.](https://www.ncbi.nlm.nih.gov/pubmed/28346074)  Pharmacogenomics. 2017 Apr;18(5):481-499. doi: 10.2217/pgs-2016-0205. Epub 2017 Mar 27. Review. PubMed PMID: 28346074; PubMed Central PMCID: PMC6219438.   Role: Conceptualization, Analysis, Writing, Corresponding Author   1. Mora E, Smith EM, Donohoe C, **Hertz DL**.  [Vincristine-induced peripheral neuropathy in pediatric cancer patients.](https://www.ncbi.nlm.nih.gov/pubmed/27904761) Am J Cancer Res. 2016 Nov 1;6(11):2416-2430. Review. PubMed PMID: 27904761; PubMed Central PMCID: PMC5126263.   Role: Conceptualization, Writing, Critical Review, Corresponding Author   1. **Hertz DL**, Rae J, [Pharmacogenetics of cancer drugs.](https://www.ncbi.nlm.nih.gov/pubmed/25386932)  (Review). Annu Rev Med 2015 Jan 14; 66:65-81. PMID: 25386932   Role: Writing, Corresponding Author   1. **Hertz DL**, McLeod HL, [Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology.](https://www.ncbi.nlm.nih.gov/pubmed/24831276) (Review). (CCR-13-2780R) Clin Cancer Res 2014 May 15;20(10):2530-40. doi: 10.1158/1078-0432.CCR-13-2780. PMID: 24831276   Role: Conceptualization, Writing   1. **Hertz DL**, [Germline pharmacogenetics of paclitaxel for cancer treatment.](https://www.ncbi.nlm.nih.gov/pubmed/23837481)  (Review). Pharmacogenomics 2013 Jul; 14(9): 1065-84. PMID: 23837481   Role: Conceptualization, Analysis, Writing, Corresponding Author   1. **Hertz DL**, McLeod HL, [Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.](https://www.ncbi.nlm.nih.gov/pubmed/23677053) (Review). J Hum Genet 2013 Jun;58(6):346-52. PMID: 23677053   Role: Writing, Corresponding Author   1. Krens SD, McLeod HL, **Hertz DL**, [Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.](https://www.ncbi.nlm.nih.gov/pubmed/23556452) (Review). Pharmacogenomics 2013;14(5):555-574. PMID: 23556452, PMCID: PMC3975654   Role: Conceptualization, Critical Review, Corresponding Author   1. **Hertz DL**, McLeod HL, Irvin WJ, [Tamoxifen and CYP2D6: a contradiction of data.](https://www.ncbi.nlm.nih.gov/pubmed/22531359)  (Review). Oncologist 2012;17(5):620-30. PMID: 22531359, PMCID: PMC3360902   Role: Analysis, Writing Editorials and Invited reviews:  1. **Hertz DL**. [Incidence, description, predictors, and consequences of persistent taxane-induced peripheral neuropathy.](https://www.ncbi.nlm.nih.gov/pubmed/38126251/)Curr Opin Support Palliat Care. 2024 Mar 1;18(1):30-38. doi: 10.1097/SPC.0000000000000684. Epub 2024 Dec 6. Review. PubMed PMID: 38126251; PubMed Central PMCID: PMC10872673.   Role: Writing, Corresponding Author   1. **Hertz DL**, Lustberg M, Sonis S. [Evolution of predictive risk factor analysis for chemotherapy-related toxicity.](https://www.ncbi.nlm.nih.gov/pubmed/37773300/)Support Care Cancer. 2023 Sep 29;31(10):601. doi: 10.1007/s00520-023-08074-x. Review. PubMed PMID: 37773300.   Role: Writing, Corresponding Author   1. Seligson ND, Kolesar JM, **Hertz DL**, Baker L, Lamba JK, Salahudeen AA, Hicks JK. [Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancer.](https://www.ncbi.nlm.nih.gov/pubmed/37702060/)Pharmacogenomics. 2023 Aug;24(13):731-738. doi: 10.2217/pgs-2023-0125. Epub 2023 Sep 13. Review. PubMed PMID: 37702060.   Role: Critical Review   1. Hertz DL. [Reply to H.S. Hochster.](https://www.ncbi.nlm.nih.gov/pubmed/36763926/)J Clin Oncol. 2023 Feb 10;:JCO2300038. doi: 10.1200/JCO.23.00038. [Epub ahead of print] PubMed PMID: 36763926.   Role: Writing, Corresponding Author   1. Baker S, Brooks G, Dahut B, Diasio RB, El-Deiry WS, Evans WE, Figg WD, **Hertz DL**, Hicks JK, Kamath S, Kasi PM, Knepper T, McLeod HL, O’Donnell P, Relling MV, Rudek M, Sissung TM, Smith DM, Sparreboom A, Swain SM, Walko C. [DPYD Testing: Time to Put Patient Safety First.](https://www.ncbi.nlm.nih.gov/pubmed/36821823/)J Clin Oncol. 2023 May 20;41(15):2701-2705. doi: 10.1200/JCO.22.02364. Epub 2023 Feb 23. PubMed PMID: 36821823; PubMed Central PMCID: PMC10414691. Role: Critical Review 2. **Hertz DL**. [Assessment of the Clinical Utility of Pretreatment *DPYD* Testing for Patients Receiving Fluoropyrimidine Chemotherapy.](https://www.ncbi.nlm.nih.gov/pubmed/36108264/)J Clin Oncol. 2022 Nov 20;40(33):3882-3892. doi: 10.1200/JCO.22.00037. Epub 2022 Sep 15. PubMed PMID: 36108264.   Role: Conceptualization, Writing, Corresponding Author   1. **Hertz DL**, McShane LM, Hayes DF, [Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective.](https://www.ncbi.nlm.nih.gov/pubmed/35324346/)J Clin Oncol. 2022;24(10):02209. doi: 10.1200/JCO.21.02209. [Epub ahead of print] PubMed PMID: 35324346.   Role: Conceptualization, Writing, Corresponding Author   1. **Hertz DL**, Ramsey LB, Gopalakrishnan M, Leeder JS, Van Driest SL. Mini-Review: [Analysis Approaches to Identify Pharmacogenetic Associations with Pharmacodynamics.](https://www.ncbi.nlm.nih.gov/pubmed/34043820/). Clin Pharmacol Ther. 2021 May 27;. doi: 10.1002/cpt.2312. [Epub ahead of print] Review. PubMed PMID: 34043820.   Role: Conceptualization, Writing, Corresponding Author   1. **Hertz DL**, Kidwell KM, Douglas JA, Viale G, Leyland-Jones B, Regan M, Rae JM. [DNA derived from archival tumor specimens can be used for germline pharmacogenetic analyses.](https://www.ncbi.nlm.nih.gov/pubmed/32723153/)Pharmacogenomics. 2020 Aug;21(13):899-902. doi: 10.2217/pgs-2020-0071. Epub 2020 Jul 29. PubMed PMID: 32723153.   Role: Conceptualization, Writing, Corresponding Author   1. **Hertz DL**, Sahai V. [Including *DPYD* on Cancer Genetic Panels to Prevent Fatal Fluoropyrimidine Toxicity.](https://www.ncbi.nlm.nih.gov/pubmed/32259779/)J Natl Compr Canc Netw. 2020 Apr;18(4):372-374. doi: 10.6004/jnccn.2019.7527. PubMed PMID: 32259779.   Role: Conceptualization, Writing, Corresponding Author   1. **Hertz DL**. [Concerns regarding use of patient-reported outcomes in biomarker studies of chemotherapy-induced peripheral neuropathy.](https://www.ncbi.nlm.nih.gov/pubmed/31395959/) Pharmacogenomics J. 2019 Oct;19(5):411-416. doi: 10.1038/s41397-019-0093-1. Epub 2019 Aug 9. Review. PubMed PMID: 31395959; PubMed Central PMCID: PMC6754778.   Role: Conceptualization, Writing, Corresponding Author   1. **Hertz DL**, Luzum JA, Pasternak AL, Ward KM, Zhu HJ, Rae JM, Ellingrod VL. [Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy.](https://www.ncbi.nlm.nih.gov/pubmed/28745551) Pharmacogenomics. 2017 Jul 26;. doi: 10.2217/pgs-2017-0107. [Epub ahead of print] PubMed PMID: 28745551.   Role: Conceptualization, Writing, Corresponding Author   1. **Hertz DL**, Rae JM. [Individualized Tamoxifen Dose Escalation-Response.](https://www.ncbi.nlm.nih.gov/pubmed/27980025) Clin Cancer Res. 2016 Dec 15;22(24):6301. PubMed PMID: 27980025. (Invited Letter to Editor Response)   Role: Conceptualization, Writing, Corresponding Author   1. **Hertz DL**, Rae JM. [One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity.](https://www.ncbi.nlm.nih.gov/pubmed/27249031) Pharmacogenomics. 2016 Jun;17(8):823-6. doi: 10.2217/pgs-2016-0059. Epub 2016 Jun 1. PubMed PMID: 27249031. (Invited Editorial)   Role: Conceptualization, Writing, Corresponding Author   1. **Hertz DL**, Rae JM. [Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility.](https://www.ncbi.nlm.nih.gov/pubmed/27012810) Clinical Cancer Research 2016 OnlineFirst March 24, 2016; doi: 10.1158/1078-0432.CCR-16-0370 (Invited Translations Commentary)   Role: Conceptualization, Writing, Corresponding Author   1. **Hertz DL**, McLeod HL. [Integrated patient and tumor genetic testing for individualized cancer therapy.](https://www.ncbi.nlm.nih.gov/pubmed/26537014) Clin Pharmacol Ther. 2016 Feb;99(2):143-6. doi: 10.1002/cpt.294. Epub 2015 Nov 25. PubMed PMID: 26537014.   Role: Conceptualization, Writing, Corresponding Author   1. **Hertz DL**, McLeod HL, Hoskins JM. [Pharmacogenetics of breast cancer therapies.](https://www.ncbi.nlm.nih.gov/pubmed/19914545)  (Review). Breast 2009 Oct;18(suppl 3):S59-63. PMID: 19914545   Role: Analysis, Writing submitted Publications:  1. Ho TT, Smith DM, Aquilante CL, Cicali EJ, El Rouby N, Hertz DL, Imanirad I, Patel JN, Scott SA, Swain SM, Tuteja S, Hicks JK. A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice. Clinical Pharmacology and Therapeutics.   Role: Conceptualization, Critical Review   1. Chen CS\*\*, Dorsch MP, Alsomairy S, Griggs JJ, Jagsi R, Sabel M, Stino A, Callaghan B, **Hertz DL**. Remote Monitoring of Chemotherapy-Induced Peripheral Neuropathy via NeuroDetect iOS App in an Observational Cohort of Patients with Cancer. JMIR   Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author   1. **Hertz DL**, Tanay M, Tofthagen C, Rossi E, Bernasconi DP, Sheffield KE, Carlson M, Nekhlyudov L, Grech L, Von Ah D, Mayo SJ, Ruddy KJ, Chan A, Alberti P, Lustberg MB,. Patient-reported Strategies for Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathy. Support Care Cancer.   Role: Conceptualization, Writing, Corresponding Author   1. Nguyen-Hoang N\*\*, Nazzal M^^, Schneider BP, Trivedi MS, **Hertz DL**. Review of the Contribution of Clinical and Genetic Factors to the Racial Disparity in Taxane-Induced Peripheral Neuropathy. Journal of the National Cancer Institute   Role: Conceptualization, Critical Review, Funding Acquisition, Corresponding Author   1. Nguyen-Hoang N\*\*, Liu Y\*\*, Henry NL, Pai MP, Zhu HJ, **Hertz DL**. Plasma proteomics to predict taxane-induced peripheral neuropathy. British Journal of Clinical Pharmacology   Role: Conceptualization, Critical Review, Corresponding Author   1. Radwan RM, Bridges JFP, **Hertz DL**, Lustberg MB, Vachhani H, Zacholski EH, Sheppard VB, Salgado TM. Factors influencing the decision to discontinue treatment due to chemotherapy-induced peripheral neuropathy among patients with metastatic breast cancer: A best-worst scaling approach. Supportive Care in Cancer  Book chapters:  1. Chen CS, **Hertz DL**. [Chemotherapy-Induced Peripheral Neuropathy.](https://www.ncbi.nlm.nih.gov/pubmed/36253554/)Handb Exp Pharmacol. 2022 Oct 18;. doi: 10.1007/164\_2022\_609. [Epub ahead of print] PubMed PMID: 36253554. 2. **Hertz DL**, Tofthagen C, Faithfull S. Predisposing factors for the development of CIPN. Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy, Pgs 19-51. Springer 2021   Role: Writing, Corresponding Author   1. Pasternak AL**, Hertz DL**. Oncology Pharmacogenomics. Pharmacogenomics: A Primer for Clinicians, McGraw Hill (In Press)   Role: Writing, Corresponding Author   1. **Hertz DL**, Rae JM, [Pharmacogenetic Predictors of Response.](https://www.ncbi.nlm.nih.gov/pubmed/26987536) Novel Biomarkers in the Continuum of Breast Cancer. Adv Exp Med Biol. 2016;882:191-215. doi: 10.1007/978-3-319-22909-6\_8. PMID: 26987536 (Book Chapter)   Role: Writing, Analysis   1. **Hertz DL**, Perissinotti AJ, Germline Pharmacogenetics in Oncology. Pharmacogenomics: Applications to Patient Care, Second Edition. ACCP. ISBN: 978-1-939862-09-9; 2015; (Book Chapter)   Role: Conceptualization, Writing, Corresponding Author   1. **Hertz DL**, McLeod HL, Cancer Pharmacogenomics (Review). Encyclopedia of Molecular Cell Biology and Molecular Medicine. Published Online: April 8, 2015. DOI: 10.1002/3527600906.mcb.201500002   Role: Analysis, Writing   1. **Hertz DL**, Ellingrod VL, Mcinnis M, Bipolar Disorder in the Cancer Patient. Psychopharmacology in Oncology and Palliative Care: A Practice Manual, Pgs 189-202 2014, Springer http://www.springer.com/us/book/9783642401336 ISBN 978-3-642-40134-3 (Book Chapter)   Role: Writing | |
| Published Abstracts | |
| 1. Norton N, Larson NB, Jenkins GD, Beumer JH, Langevin B, Gobbaru J, Morris MJ, Heller G, Nakamura Y, Kubo M, Kroetz D, Zhu HJ, O’Donnell PH, Lewis LD, **Hertz DL**. Association of SULT2A1 with abiraterone clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer. American Society of Human Genetics (ASHG) Annual Meeting. Poster 2024-A-1343-ASHG. November 5-9, Denver, CO. 2. Klima F, Helland T, Michelet R, Huisinga W, **Hertz DL**, Kloft C, On behalf of the CYP2D6 Endoxifen Percentage Activity Model in Breast Cancer (CEPAM) Consortium. Quantifying the impact of CYP2D6 allele activity on Z-endoxifen formation leveraging the multi-study CEPAM database: Towards treatment optimisation of tamoxifen. Population Approach Group Europe (PAGE). June 25-28, 2024 Rome, Italy. 3. Tanay ML, Tofthagen C, Bernasconi DP, Rossi E, Von Ah D, Sheffield KE, Mayo S, Nekhlyudov L, Grech L, Ruddy KJ, Chan A, Alberti P, **Hertz DL**, Lustberg MB. MASCC Patient Survey of Strategies used for Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathy (CIPN). E-Poster Presented at MASCC 2024 Annual Meeting. Lille, France June 28, 2024. Abstract 2578 4. Jun Y, Tao X, Chen CS, Griggs JJ, Kidwell KM, **Hertz DL**. Impact of Chemotherapy-induced Peripheral Neuropathy Permanence on Patient Preference to Discontinue Chemotherapy Treatment. Poster presentation at ASCO Annual Meeting 2024. Abs 12046. June 3, 2024 5. Trivedi MS, Unger JM, Henry NL, Darke AK, **Hertz DL**, Brannagan TH, Smith SJ, Schneider BP, Irvin Jr WJ, Hathaway AR, Vander Woude AC, Gudena VK, Cabrera-Galeana P, Orsted M, LeBlanc M, Fisch MJ, Hershman DL: Risk prediction model for taxane-induced peripheral neuropathy (TIPN) in patients with early-stage cancer receiving taxane therapy: SWOG S1714. Oral presentation at ASCO Annual Meeting 2024. Abs 12005. June 2, 2023 6. Tracksdorf T, Pearse S, Smith DM, Scott SA, Ho TT, Aquilante CL, Patel JN, Cicali EJ, Hicks JK, **Hertz DL**. Survey of Implementation Strategies for *DPYD* Testing Prior to Fluoropyrimidine Chemotherapy in the USA. 2024 MASCC Annual Meeting. June 27-29, 2024. Lillie, France 7. Banerjee S, Thomas F, **Hertz DL**. *DPYD* Variants and Association with Fluoropyrimidine Toxicity in Asian Patients. 2024 MASCC Annual Meeting. June 27-29, 2024. Lillie, France 8. Vanderwerff B, Pasternak AL, Fritsche LG, Bertucci-Richter E, Patil S, Boehnke M, Zhou X, Zöllner S, **Hertz DL**, and Zawistowski M. Inference and characterization of CYP2D6 whole gene deletions from a SNP array in the Michigan Genomics Initiative biobank. American Society of Human Genetics 2023 Annual Meeting, Washington, D.C., November 2023. 9. Chen CS\*\*, Stringer KA, Karnovsky A, Henry NL, **Hertz DL**. Identification of Lipidomics Predictors of Sensory Paclitaxel-induced Peripheral Neuropathy. E-Poster Presented at MASCC 2023 Annual Meeting, Nara, Japan July 2023. 10. Granados J^^, Pasternak AL, Henry NL, Sahai V, **Hertz DL.** Risk of Severe Toxicity from Topical Fluoropyrimidine Treatment in Patients Carrying *DPYD* Variant Alleles. Symptoms and Survivorship Poster Session, ASCO Annual Meeting 2023, Chicago, IL. Abs 12123. 11. Tanay M, **Hertz DL**, Lustberg M, Tofthagen C, Ruddy K, Chan A, Alberti P, Rossi E, Sheffield K, Nekhlyudov L, Mayo S, Von Ah D, Loprinzi C, Grech L, Quan Ng D, Gordon S, Bernasconi D. Patient experiences of communicating chemotherapy-induced peripheral neurotoxicity, treatment decisions and management practices: an online survey. E-Poster Presented at MASCC 2023 Annual Meeting. 12. Trivedi MS, Unger JM, Hershman DL, Darke AK, **Hertz DL**, Brannagan TH, Smith SJ, Schneider BP, Irvin Jr WJ, Hathaway AR, Vander Woude AC, Gudena VK, Henry NL, Fisch MJ, Chemotherapy Induced Peripheral Neuropathy due to Paclitaxel versus Docetaxel in Patients with Early-Stage Breast Cancer Receiving Taxane Therapy: SWOG S1714 (NCT# 03939481). Oral presentation at ASCO Annual Meeting 2023. Abs 12003. 13. Radwan RM, **Hertz DL**, Zacholski EH, Vachhani H, Lustberg MB, Bridges JFP, Sabo RT, Sheppard VB, Salgado TM. Identifying Factors that influence the decision to reduce, delay, or discontinue treatment due to chemotherapy-induced peripheral neuropathy: A community-centered approach. ASCO Annual Meeting, Chicago, Illinois, June 2023 (online publication) 14. Trivedi MS, Unger JM, Hershman DL, Darke AK, **Hertz DL**, Brannagan TH, Smith SJ, Schneider BP, Irvin Jr WJ, Hathaway AR, Vander Woude AC, Gudena VK, Henry NL, Fisch MJ, Incidence of Acute and Persistent Clinically Meaningful Chemotherapy Induced Peripheral Neuropathy in Patients with Early-Stage Breast Cancer Receiving Taxane Therapy: SWOG S1714 (NCT# 03939481). San Antonio Breast Cancer Symposium 2022. Poster Discussion PD8-06. Presented December 7, 2022 15. Chen CS\*\*, Zirpoli G, McCann SE, Barlow WE, Budd GT, Pusztai L, Hortobagyi GN, Godwin AK, Thompson A, Ambrosone CB, Stringer KA, **Hertz DL**. Vitamin D Insufficiency as a Peripheral Neuropathy Risk Factor in White and Black Patients in SWOG 0221. Symptoms and Survivorship Poster discussion at ASCO Annual Meeting 2022. Abs 12023. J Clin Oncol 40, 2022 (suppl 16; abstr 12023). DOI: [10.1200/JCO.2022.40.16\_suppl.12023](https://doi.org/10.1200/JCO.2022.40.16_suppl.12023) 16. Trivedi MS, Unger JM, Hershman DL, Darke A, **Hertz DL**, Brannagan T, Smith S, Irvin WJ, Hathaway AR, Vander Woude AC, Gudena VK, Henry NL, Fisch MJ. Differences in clinician and patient assessment of baseline neuropathy in patients receiving taxane-based chemotherapy enrolled to SWOG S1714 (NCT# 03939481). Poster discussion presented at ASCO Annual Meeting 2022. Abs 12023. J Clin Oncol 40, 2022 (suppl 16; abstr 12024). DOI: [10.1200/JCO.2022.40.16\_suppl.12024](https://doi.org/10.1200/JCO.2022.40.16_suppl.12024) 17. McLaughlin AM, Helland T^, Michelet R, Mikus G, **Hertz DL**, Kloft C. Between-Assay Variability Might Explain Differences in Proposed Z-Endoxifen Efficacy Thresholds – Exploratory Analysis Results of the CYP2D6 Percentage Activity Endoxifen Model in Breast Cancer (CEPAM) Consortium Database. Poster presented virtually at: 2022 American Society of Clinical Pharmacology and Therapeutics Annual Meeting 18. Chen CS\*\*, Stringer KA, Henry NL, **Hertz DL**. Metabolomics and nutritional biomarkers of motor chemotherapy-induced peripheral neuropathy. Poster presented at: Metabolomics Association of North America (MANA) 2021 Virtual Conference; October 18-21; Columbus, Ohio. 19. Koo K\*, Pasternak AL, **Hertz DL**, Survey of U.S. Medical Oncologists’ Practices and Beliefs regarding *DPYD* Testing Prior to Fluoropyrimidine Chemotherapy. Poster presented virtually at: 2021 Pharmacogenomics Global Research Network Annual Meeting; Oct 18, 2021 20. **Hertz DL,** Pasternak AL, Henry NL, Sahai V. Feasibility and Efficiency of Confirmatory *DPYD* Testing Only in Suspected Carriers Within an Institutional Genetics Data Repository. Poster presented virtually at: 2021 American Society of Clinical Pharmacology and Therapeutics Annual Meeting; March. 12, 2021 21. **Hertz DL**, Dockter TJ, Satele DV, Le-Rademacher J, Loprinzi CL Neuropathy Severity at the Time of Oxaliplatin Treatment Alteration in Patients with Colon Cancer (A151912). ASCO Annual Meeting 2021 Presented Virtually; Abstract 12090 22. **Hertz DL**, Smith KL, Zong Y, Gersch CL, Pesch AM, Patel A\*, Lehman J, Henry NL, Kidwell KM, Rae JM, Stearns V. Association of OPG rs2073618 and aromatase inhibitor-induced musculoskeletal symptoms. 2020 San Antonio Breast Cancer Symposium®, December 9, 2020, PS5-25 23. Shakeel F^, Fang F, Kwon JW\*, Koo K\*, Pasternak AL, Henry NL, Sahai V, Kidwell KM, **Hertz DL**. Carriers of *DPYD* polymorphisms have increased risk of severe toxicity and related treatment modifications when receiving fluoropyrimidine chemotherapy. PGRN Annual Meeting. Oct 26, 2020 24. Helland T^, Baurley J, Fabienne FT, Mellgren G, Swen JJ, Brauch H, Gaedigk A, **Hertz DL**. Development of a CYP2D6 Percentage Activity System. PGRN Annual Meeting. Oct 26, 2020 25. Lin C\*, Helland T^, **Hertz DL**. The Impact of CYP3A4/5 Genetics and Drug Interactions on Tamoxifen and Metabolite Concentrations. PGRN Annual Meeting. Oct 26, 2020 26. Chen CS\*\*, Kim J\*, Guntupalli H\*, Dorsch M, Callaghan B, Garg N^^, Jagsi R, Griggs JJ, Sabel M, **Hertz DL**. Initial pilot testing of a smartphone app for detection of chemotherapy-induced peripheral neuropathy. ASCO Quality Care Symposium. October 9-10, 2020. Presented Virtually; Abstract 176. 27. **Hertz DL**, Douglas JA, Kidwell KM, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. Genome-wide association study of steady-state letrozole concentration in patients with breast cancer. May 29-June 2, 2020; ASCO Annual Meeting 2020 Presented Virtually; Abstract 538. 28. **Hertz DL**, Larson N, Pierpont TM, Bartlett N, Zelenetz AD, Wilson W, Leonard J, Jung SH, Riska S, Richards KL Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy (PN) in patients with diffuse large B-cell lymphoma on CALGB 50303 (Alliance). ASCO Annual Meeting 2020. Published online: ASCO Meeting Library. Abstract e13535 29. **Hertz DL,** Rutherford D, Gersch CL, Holdentrieder S, Mayer Z, Rossler M, Joerger M. *EPHA5* rs7349683 is Not Associated with CIPN-Sensitivity in Lung Cancer Patients Receiving Paclitaxel TDM. Poster presented at: 2020 American Society of Clinical Pharmacology and Therapeutics Annual Meeting; March. 19, 2020; Houston, TX 30. Helland T^, Baurley J, Thomas-Jean F, Mellgren G, Swenn JJ, Brauch H, Gaedigk A, and **Hertz DL**. Consensus CYP2D6 translation system improves explanation of tamoxifen bioactivation in analysis of 15 multi-racial cohorts. Poster presented at: 2020 American Society of Clinical Pharmacology and Therapeutics Annual Meeting; March. 18, 2020; Houston, TX 31. Marcath LA^, Finley CM\*, Wong SF, and **Hertz DL**. Prevalence of drug-drug interactions in oncology patients enrolled in two completed SWOG clinical trials. Poster presented at: 2019 American College of Clinical Pharmacology Annual Meeting; Sept. 15, 2019; Chicago, IL 32. Jennaro T\*\*, Smith EM, Vangipuram K\*, Kidwell KM, Burness M, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Henry NL, **Hertz DL**. Vitamin D Insufficiency and Risk of Paclitaxel-Induced Peripheral Neuropathy [abstract].; May 31-June 4, 2019; Chicago, IL. Published online: ASCO Meeting Library; May 15, 2019. Abstract e12027 33. Marcath LA^, Kidwell KM, Lavoie Smith EM, Vangipuram K, Gersch C, Burness ML, Griggs JJ, Van Poznak C, Hayes DF, Henry NL, Beutler AS, and **Hertz DL**. *EPHA* genetics for prediction of paclitaxel-induced peripheral neuropathy sensitivity [abstract].; May 31-June 4, 2019; Chicago, IL. Published online: ASCO Meeting Library; May 15, 2019. Abstract 532. 34. Marcath LA^, Coe TD, Redman BG, **Hertz DL**. Development of a drug-drug interaction screening tool for oncology clinical trial enrollment [abstract]. Sept. 28-29, 2018; Phoenix, AZ. Published online: ASCO Meeting Library; Sept. 24, 2018. Abstract 315. 35. Wang H, **Hertz DL**, Henry NL Gobburu J, Ivaturi V. Population Pharmacokinetics of Paclitaxel in Breast Cancer Patients. 2018 American College of Clinical Pharmacology (ACCP) Annual Meeting. Bethesda, MD, September 23-25, 2018 36. Dempsey JM\*, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM, **Hertz DL**. Association of a Low-Expression *SLCO1B1* Polymorphism with Estrogen Concentrations Before and During Aromatase Inhibitor Treatment for Breast Cancer. General Poster Session Abs # 543, American Society of Clinical Oncology Annual Meeting, June 2, 2018 37. Marcath LA\*, Coe TD, Hoylman EK, Redman BG, and **Hertz DL**. Prevalence of clinically relevant drug-drug interactions in patients enrolled in NCTN clinical trials [abstract]. June 1-5, 2018; Chicago, IL. Published online: ASCO Meeting Library; May 16, 2018. Abstract e18819. 38. Salgado TM, Syverson JG, Reed HL, Quinn CS, Krumbach E, Farris KB, **Hertz DL**. Factors associated with under-reporting of peripheral neuropathy symptoms in women with breast cancer receiving paclitaxel. 20th International Social Pharmacy Workshop, Leuven, Belgium, July 2018. 39. Marcath LA^, Xi J, Hoylman E, Kidwell K, Kraft S, **Hertz DL**. Comparison of nine drug-drug interaction screening tools when assessing oral oncolytics. Abs P1-114. American Society of Clinical Pharmacology and Therapeutics Annual Meeting, March 22, 2018. 40. Sun Y^, Mchugh C, Henry NL, Stringer KA, **Hertz DL**. Quantitative Nuclear Magnetic Resonance (1H-NMR) Pharmacometabolomics to Predict and Understand Paclitaxel-induced Neuropathy in Breast Cancer Patients. Abs P1-146. American Society of Clinical Pharmacology and Therapeutics Annual Meeting, March 22, 2018. 41. Pasternak AL^, Kidwell KM, Dempsey J, Sun Y, **Hertz DL**, Park JM. The Impact of *CYP3A5* Genotype on Tacrolimus Trough Concentrations Varies Between Routes of Administration. Abs P1-125. American Society of Clinical Pharmacology and Therapeutics Annual Meeting, March 22, 2018. 42. **Hertz DL,** Kidwell KM, Vangipuram K\*, Sun D, Henry NL. Association of systemic paclitaxel concentrations with severity and progression of paclitaxel-induced peripheral neuropathy. General Poster Session Abs #1078, P6-11-03, San Antonio Breast Cancer Symposium, December 9, 2017 43. Krumbach E\*, Nobles B, Erickson S, Farris KB, **Hertz DL**. The Role of Patient Perceptions in Under Reporting Chemotherapy Induced Peripheral Neuropathy (CIPN). General Poster Session Abs #662, P4-11-06, San Antonio Breast Cancer Symposium, December 8, 2017 44. **Hertz DL,** Kidwell KM, Speth KA, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. Is incomplete estradiol suppression during aromatase inhibitor treatment in post-menopausal patients with breast cancer due to insufficient systemic drug concentrations? General Poster Session Abs #1063, American Society of Clinical Oncology Annual Meeting, June 4, 2017 45. Marcath L\*, Deal AM, Desta Z, McLeod HL, Carey LA, Irvin Jr WJ, **Hertz DL**. The association of cytochromes P450 and transporter genetic variation with steady-state endoxifen concentration. American Society of Clinical Pharmacology and Therapeutics Annual Meeting, March 16, 2017 and ASHP Midyear Clinical Meeting 2016 46. **Hertz DL,** Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. Genetic variation in CYP3A affects steady-state exemestane concentrations but does not explain inter-race difference. (General Poster Session Abs P6-09-11) San Antonio Breast Cancer Symposium December 10, 2016 47. **Hertz DL**, Robinson D, Lonigro R, Wu YM, Vats P, Cao C, Nobani A, Mora E, Chinnaiyan AM, Mody R. Clinically actionable pharmacogenetic variants identified during tumor genetic profiling in pediatric cancer patients. General Poster Session Abs#1583. American Society of Clinical Oncology Annual Meeting, June 6, 2016 48. Van Wieren E\*, Kidwell KM, Desta Z, McLeod HL, Carey LA, Irvin Jr WJ., **Hertz DL**. Assessment of a clinical and genetic algorithm to predict endoxifen concentration. Publication Only Abs#e12021. American Society of Clinical Oncology Annual Meeting 2016 49. Patel JN, Jiang C, Owzar K, **Hertz DL**, Mulkey FA, Kelly WK, Halabi S, Furukawa Y, Lassiter C, Dorsey SG, Friedman PN, Small EJ, Febbo PG, Kroetz DL, Carducci MA, Mahoney JF, Kelley MJ, Nakamura Y, Kubo M, Ratain MJ, Morris MJ, McLeod HL. A discovery analysis to identify clinical and genetic risk factors for gastrointestinal (GI) hemorrhage (HEM) in CALGB 90401 (Alliance) American Association of Clinical Research Annual Meeting April 18, 2016, New Orleans, Louisiana (Abs# 2037) 50. Nguyen H\*, Sun D, Henry NL, **Hertz DL**,Pharmacokinetic Prediction of Paclitaxel Induced Peripheral Neuropathy. (Quantitative Pharmacology Poster Session Abs 475) American Society of Clinical Pharmacology and Therapeutics March 10, 2016 and ASHP Midyear Clinical Meeting Abs 7-142 December 9, 2015 51. **Hertz DL**, Danko W\*, Deal A, Walko CM, Flockhart DA, McLeod HL, Ibrahim JG, Irvin Jr WJ. Comprehensive assessment of the effect of genetic polymorphisms in drug metabolizing enzymes and transporters on tamoxifen activation to endoxifen. (General Poster Session Abs P5-12-06) San Antonio Breast Cancer Symposium December 11, 2015 52. **Hertz DL**, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. CYP3A4\*22 polymorphism is associated with increased exemestane concentrations in postmenopausal breast cancer patients (General Poster Session P5-12-05) San Antonio Breast Cancer Symposium December 11, 2015 53. Ahern TP, **Hertz DL**, Damkier P, Ejlertsen B, Hamilton-Dutoit SJ, Rae JM, Regan MM, Thompson AM, Lash TL, Cronin-Fenton DP. CYP2D6 genotype and breast cancer recurrence in tamoxifen treated patients: an evaluation of the importance of loss-of-heterozygosity. (General Poster Session Abs P3-07-23) San Antonio Breast Cancer Symposium December 10, 2015. 54. Kidwell KM, **Hertz DL**, Leyland-Jones B, Regan MM, Dowsett M, Rae JM. Analysis of the International tamoxifen pharmacogenomics consortium (ITPC) dataset shows that genotyping DNA derived from tumor does not introduce CYP2D6 genotyping error or mask an association with tamoxifen efficacy. (General Poster Session Abs P6-09-02) San Antonio Breast Cancer Symposium December 10, 2015. 55. **Hertz DL,** Kidwell KM, Thibert JN, Gersch CL, Regan MM, Skaar TC, Henry NL, Hayes DF, Van Poznak C, Rae JM. Comparison of genotyping performance in DNA extracted from matched FFPE tumor, FFPE lymph node, and whole blood for pharmacogenetic analyses. General Poster Session #352. 2015 American Society of Clinical Oncology Annual Meeting, June 1, 2015 56. **Hertz DL**, Snavely AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S, Weck KE, Rubin P, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Peppercorn JM, Evans JP, Desta Z, Flockhart DA, Carey LA, Irvin WJ. CYP2D6 Intermediate metabolizers includes patient groups with distinct metabolic activity (General Poster Session, Abs P1-03-02) San Antonio Breast Cancer Symposium Dec 10, 2014. 57. **Hertz DL**, Jiang C, Owzar K, Halabi S, Kelly WK, Mulkey FA, Patel JN, Carducci MA, Kelley MJ, Stadler WM, Mohamed M, Morris MJ, Nakamura Y, Zembutsu H, Ratain MJ, McLeod HL. A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance). General Poster Session #9612. 2014 American Society of Clinical Oncology Annual Meeting, June 1, 2014 58. **Hertz DL**, Snavely A, Evans JP, Ibrahim JG, Anderson S, Friedman K, Weck KE, Rubin P, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schartz G, Peppercorn JM, Graham ML, Canale ST, McLeod HL, Carey LA, Irvin Jr WJ, Does increasing the daily tamoxifen dose in patients with diminished CYP2D6 activity increase toxicity? General Poster Session #561. 2014 American Society of Clinical Oncology Annual Meeting, June 2, 2014 59. Patel JN, Jiang C, **Hertz DL**, Mulkey FA, Friedman PN, Halabi S, Ratain MJ, Morris MJ, Small EJ, Owzar K, Kelly WK, McLeod HL. Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (Alliance). Publication only #e16061. American Society of Clinical Oncology 2014 Annual Meeting 60. Patel JN, Jiang C, **Hertz DL**, Mulkey FA, Friedman PN, Halabi S, Ratain MJ, Morris MJ, Small EJ, Owzar K, Kelly WK, McLeod HL. Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (Alliance). General Poster Session Abstract #3841. American Association of Clinical Research April 8, 2014. 61. **Hertz DL**, Owzar K, Halabi S, Kelly WK, Zembutsu H, Jiang C, Patel NJ, Watson D, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Small EJ, Febbo PG, Nakamura Y, Kubo M, Ratain MJ, McLeod HL. A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401(ALLIANCE). J Clin oncol 31, 2013 (suppl; abstr 11053) General Poster Session, Tumor Biology, American Society of Clinical Oncology, June 3, 2013 62. **Hertz DL**, Dees EC, Roy S, Motsinger-Reif AA, Drobish A, McLeod HL, Carey LA. Patients Carrying CYP2C8\*3 are at Increased Risk of Paclitaxel-Induced Neuropathy (Poster Discussion: PD 10-07) San Antonio Breast Cancer Symposium Dec 7, 2012 63. **Hertz DL**, Crona D, Talameh J, Brantley S, Roode L, Theken K, Zafir B, Hull JH. Integration of Scientific Writing into an Applied Biostatistics and SAS Programming Course for Pharmaceutical Sciences Graduate Students (Poster: P0-11, Manuscript: <http://analytics.ncsu.edu/sesug/2012/PO-11.pdf>) South East SAS Users Group 2012 Conference Oct 14, 2012 64. **Hertz DL**, Dees EC, Motsinger-Reif AA, Drobish A, Roy S, McLeod HL, Carey LA. Interrogation of polymorphisms in drug metabolism or transport genes and peripheral neuropathy during paclitaxel treatment. J Clin Oncol 30, 2012 (suppl; abstr 10515) Poster Discussion, American Society of Clinical Oncology, June 5, 2012 65. **Hertz DL**, Dees EC, Motsinger-Reif AA, Drobish A, Winham S, McLeod HL, Carey LA. Breast Cancer Patients Carrying the CYP2C8\*3 Variant are More Likely to Achieve Clinical Complete Response from Neoadjuvant Paclitaxel Treatment (Poster Discussion: PD 07-10) San Antonio Breast Cancer Symposium Dec 11, 2010 | |
| \*Denotes PharmD Investigations Student  \*\*Denotes PhD Student  ^Denotes Post-Doctoral Fellow  ^^Denotes undergraduate, BSPS Student, MSIPS, or other trainee  Research Funding | |
| ACTIVE 1R37CA277043-01 (Co-PI: Daniel L Hertz) 1/1/2023-12/31/2027  National Cancer Institute R37  $3,194,474  *Development of an Integrated Risk Prediction Model of Taxane-induced Peripheral Neuropathy*  The major goals of this project are to discover and validate physiologic biomarkers that predict taxane-induced peripheral neuropathy  Role: Submitting Co-Principal Investigator (25% effort)  N030566-497333 AWD017705 (PI: Daniel L Hertz) 7/1/2021-6/30/2025  American Cancer Society Research Scholars Grant $761,245  *Nutrient Insufficiency and Peripheral Neuropathy Risk*  The major goals of this project are to validate vitamin D and histidine insufficiency as predictors of paclitaxel-induced peripheral neuropathy in SWOG 0221  Role: Principal Investigator (20% effort)  TLC-22-189-01-TLC (Co-PI: Daniel L Hertz) 1/1/2023-12/31/2023  American Cancer Society Research Scholars Grant $30,000  *Assessment of Mastectomy-related Range of Motion Deficits via Smartphone App*  The major goals of this project are to determine whether our novel MotionDetect iPhone app can detect limitations in arm range of motion caused by surgical mastectomy  Role: Co-Principal Investigator (4% effort)  U087115-428121 (PI: Daniel L Hertz) 6/1/2024-5/31/2025  UM Rogel Cancer Center Translational Award $150,000  *Personalized Taxane Infusion Rate Recommendations to Reduce Neuropathy Risk in Patients with Low Skeletal Muscle Area*  The major goals of this project are to determine whether our skeletal muscle area is associated with systemic taxane exposure and can be used to personalize dosing to reduce peripheral neuropathy  Role: Principal Investigator (5% effort) PendingCompleted No Number Assigned (PI: Daniel L Hertz) 9/1/2021-8/31/2022  MICHR Catalyst Award $24,861  *Lipidomic and Proteomic Biomarkers of Paclitaxel-induced Peripheral Neuropathy*  The major goals of this project are to discover lipidomic and proteomic biomarkers that predict severity of paclitaxel-induced peripheral neuropathy in UMCC2014.002  Role: Principal Investigator (5% effort)  No Number Assigned (PI: Daniel L Hertz) 7/1/2019-6/30/2020  MICHR Pathway to Independence $75,000  *Development of a Mobile App to Monitor Chemotherapy-Induced Neuropathy*  The major goals of this project are to continue development of our neuropathy detection app and test whether it detects neuropathy in a study of patients undergoing neurotoxic chemotherapy.  Role: PI (8% effort)  No Number Assigned (PI: Daniel L Hertz) 1/1/2020-6/30/2021  HOPE Foundation SEED Grant $50,000  *Prospective Drug-Drug Interaction Screening in SWOG Clinical Trials*  Determine whether implementation of a drug-drug interaction screening tool improves effectiveness and efficiency of screening in patients enrolling in oncology clinical trials.  Role: PI (0% effort)  No Number Assigned (PI: Daniel L Hertz) 10/1/2020-9/30/2021  Rogel Discovery Award $75,000  *Vitamin D Deficiency and Risk of Paclitaxel-induced Peripheral Neuropathy in Patients on SWOG 0221*  The major goal of this project is to determine whether vitamin D deficiency increases risk of paclitaxel induced peripheral neuropathy in SWOG 0221.  Role: PI (0% effort)  N018819 (PI: Amy Pasternak) 1/1/2019-12/31/2019  AACP New Investigator Award $50,000  *Defining the pharmacogenetic associations for CYP3A5 and IV tacrolimus*  The major goals of this project are to understand the pharmacogenomic relationship between CYP3A5 polymorphisms and steady state tacrolimus concentrations in patients receiving IV treatment.  Role: Mentor (0% effort)  No Number Assigned (PI: Daniel L Hertz) 5/1/2019-4/30/2020  Disarm Therapeutics $20,000  *NfL as a plasma biomarker of chemotherapy-induced peripheral neuropathy*  The major goal of this project is to test whether plasma NfL is an objective, measurable indicator of the severity of neuropathy in patients receiving paclitaxel treatment.  Role: Co-investigator (3% effort)  No Number Assigned (PI: Daniel L Hertz) 7/1/2016-6/30/2017  MICHR Pilot $50,000  *Genetic and Kinetic Predictors of Ineffective Estradiol Depletion During Aromatase Inhibitor Treatment*  The major goals of this project are to discover kinetic and genetic predictors of ineffective estradiol depletion during aromatase inhibitor (exemestane and letrozole) treatment in patients with estrogen-receptor positive breast cancer.  Role: PI (5% effort)  No Number Assigned (PI: Daniel L Hertz) 3/1/2016-2/28/2017  Hope Foundation $50,000  *Kinetic and genetic predictors of estradiol depletion in SWOG0226*  The major goals of this project are to discover kinetic and genetic predictors of ineffective estradiol depletion during aromatase inhibitor (anastrozole) treatment in patients with estrogen-receptor positive breast cancer.  Role: PI (no effort)  U050294 (PI: Daniel L Hertz) 12/1/2015-11/30/2016  MICHR SEED $5,000  *Frequency and Causes of Patient Underreporting of Peripheral Neuropathy*  The major goals of this project are to document the discrepancy between patient-reported and clinician documented peripheral neuropathy and to identify patient-specific attitudes and beliefs that are associated with non-disclosure of neuropathy during paclitaxel treatment.  Role: PI (no effort)  N018819 (PI: James M. Rae) 10/1/2015-9/30/2023  Breast Cancer Research Foundation $250,000 (annual)  *Pharmacogenomic Predictors of Breast Cancer Endocrine Response*  The major goals of this project are to discover pharmacogenomic predictors of breast cancer patient’s response to and toxicity from endocrine therapy.  Role: Co-investigator (9% effort)  Role: Co-investigator (9% effort)  5KL2RR024987 (PI: Thomas P. Shanley) 6/1/2015-5/31/2017  MICHR KL2 Career Development Award (Awarded to Daniel L Hertz) $210,665  *Identification of neuropathy predictors for individualized paclitaxel treatment*  The major goals of this project are to define the association between cumulative paclitaxel exposure and neuropathy development to assist in development of tools for personalized dosing and to provide mentored experiential training to the PI.  Role: Awardee (75% effort)  No Number Assigned (PI: Daniel L Hertz) 1/1/2016-12/31/2016  AACP New Investigator Award $10,000  *Identification of pharmacogenetic predictors of endocrine treatment for breast cancer*  The major goals of this project are to discover the genetic variants responsible for determining concentrations of anastrozole and fulvestrant in post-menopausal patients with metastatic estrogen-receptor positive metastatic breast cancer.  Role: PI (0% effort)  No Number Assigned (PI: Yang, Zhang) 1/1/16-12/31/17  University of Michigan MCubed $60,000  *Understanding personalized chemotherapy-induced neuropathy by virtual GPCR screening and clinical evaluation*  The major goals of this project are to use combined in silico and clinical pharmacogenetics approaches to understand the role of GPCR in chemotherapy-induced peripheral neuropathy  Role: Co-Investigator  Invited Presentations | |
| National/International2024 Preventing severe fluoropyrimidine induced toxicities in the US - the impact of genetic diversity on testing decisions. International Association of Therapeutic Drug Monitoring and Clinical Therapeutics (IATDMCT). Invited Presentation. September 16, 2024. Banff, AB, Canada 2023 Correlative Symptom Science in NCTN. Alliance Spring 2023 Symptom Intervention Committee. May 4, 2023  Alliance Trial of *DPYD*-Guided Fluoropyrimidine Treatment. Alliance Spring 2023 GI Committee. May 4, 2023  Pre-treatment *DPYD* testing to Prevent Severe Fluoropyrimidine Toxicity. John’s Hopkins University Clinical Pharmacology Grand Rounds. May 3, 2023  FDA Denial of Petition to Recommend FP Dose Adjustment in *DPYD* Carriers. CPIC Monthly Meeting. February 2, 2023.  Evidence Supporting Universal *DPYD* Testing Prior to Fluoropyrimidine Chemotherapy. PMWC Annual Meeting. San Jose, CA. January 27, 2023. 2022 Opportunities and Challenges as a Translational Symptom Scientist at SWOG. October 20, 2022 SWOG Group Meeting Fall 2022  *CYP2D6* Endoxifen Percentage Activity Model (CEPAM) Project Objectives. July 8, 2022. PGRN RIPS Seminar  Wearable Devices and Apps for Remote Monitoring of Chemotherapy Induced Peripheral Neuropathy. May 16, 2022. Peripheral Nerve Society Annual Meeting  *DPYD* Testing to Ensure Safe Fluoropyrimidine Treatment. 3rd Annual Global Colorectal Cancer Congress. April 1, 2022    Pharmacogenetics and Biomarkers of Cancer Treatment Toxicity. National Taiwan University School of Pharmacy Research Day and International Conference. May 5, 2022  Analysis Approaches to Identify PGx associations with pharmacodynamics. PGRN Best Practices Monthly Seminar. January 21, 2022  PQI Review: Recommendation for pre-treatment DPYD testing prior to Fluoropyrimidine Chemotherapy. NCODA International Monthly Meeting. January 20, 2022  Evidence Supporting Universal Pre-treatment *DPYD* Testing. National Cancer Institute PDQ Cancer Genetics Editorial Board Meeting. January 18, 2022 2021 Confirmatory PGx Testing Using an Institutional Genetic Data Repository. IGNITE Steering Committee Meeting. September 23, 2021  Predictive Biomarkers of Taxane-induced Peripheral Neuropathy in Patients with Cancer. UNC DPET Seminar Guest Lecture. Sept 21, 2021  Efforts Toward Universal Implementation of DPYD Testing. Georgetown University Lombardi Comprehensive Cancer Center Oncology Grand Rounds Lecture. Sept 19, 2021  The Role for Genetic Counselors in *DPYD* Testing and Counseling to Advocate for Safe Cancer Treatment. NSGC Cancer SIG. August 4, 2021  Personalizing Supportive Care Through Genomics. Discussant, Symptoms and Survivorship Oral Abstract Session. ASCO Annual Meeting 2021 Presented Virtually. Friday June 4, 2021  Efficient Implementation of DPYD Testing Using an Institutional Genetics Data Repository. Genetics Virtual Week. April 20, 2021  Predictors of Paclitaxel-induced Peripheral Neuropathy in Patients with Breast Cancer. Toxic Neuropathy Consortium. March 25, 2021  Evidence Supporting Pre-treatment DPYD Testing. Precision Medicine Leadership Summit, March 2, 2021  Treatment Alteration due to Chemotherapy-induced Peripheral Neuropathy (CIPN). MASCC Neurological Complications Study Group. February 4, 2021 2020 FDA Petition for Pre-treatment *DPYD* testing. Clinical Pharmacogenetics Implementation Consortium December Members Meeting, Dec 3, 2020  Predictors of Taxane-induced Peripheral Neuropathy in Patients with Cancer. VCU Translational Research in Peripheral Neuropathy Seminar. Jan 30, 2020 2019 Embedded Prospective PGx Substudies, Alliance Pharmacogenetics and Population Pharmacokinetics (PPP) Committee. May 10, 2019  Drug-Drug Interaction (DDI) Screening for Oncology Clinical Trial Enrollment. Oishi Symposium, SWOG Spring 2019 Meeting, April 25, 2019 2018 Phenomics in Pharmacogenomics, Alliance Pharmacogenetics and Population Pharmacokinetics (PPP) Committee. May 11, 2018  Pharmacometabolomics of Paclitaxel-induced Peripheral Neuropathy (PIPN). SWOG Breast Translational Medicine Committee. April 13, 2018 2017 Comprehensive PGx Evaluation of Steady-State Endoxifen Concentration in Tamoxifen Treated Patients, Alliance Pharmacogenetics and Population Pharmacokinetics (PPP) Committee. May 12, 2017  Drug Interaction Screening Tool for Clinical Trial Enrollment. SWOG Cancer Care and Delivery Committee. April 27, 2017 2016 Pharmacogenetics of Taxane-Induced Peripheral Neuropathy. SWOG Symptom Control and Quality of Life Committee. September 15, 2016.  Translational Studies of Anastrozole and Fulvestrant PK and PD in S0226. SWOG Breast Translational Medicine Committee. April 29, 2016  Pharmacogenetic Discovery in Cooperative Group Trials. SWOG Pharmacogenomics Committee. April 29, 2016 2014 GWAS of Taxane-Induced Neuropathy in CALGB Clinical Trials. Alliance Pharmacogenetics and Population Pharmacokinetics (PPP) Committee. Nov 7, 2014  Application of Pharmacogenomics to Minimize Chemotherapy Toxicity. Education Session: Pharmacogenomics in the Era of Next Generation Sequencing. American Society of Clinical Oncology 2014 Annual Meeting  Pharmacogenetics of docetaxel toxicity in CALGB/Alliance 90401. Alliance GU Committee. May 10, 2014 2013 Neutropenia Pharmacogenetics in Prostate Cancer (CALGB 90401). Alliance PPP Committee. March 13, 2013 2012 Pharmacogenomics: Translation and Implementation. 31st NSGC Annual Education Conference Oct 26, 2012  Neuropathy Pharmacogenomics in Prostate Cancer (CALGB 90401). PGRN-RIKEN Collaboration Meeting Oct 4, 2012, Alliance PPP Committee Nov 15, 2012 Local/State2024 Confirmatory Testing of Actionable Pharmacogenetic Genotypes for Clinical Use. MGI Sympsosium September 20, 2024.  Translational Pharmacogenetics (PGx) to Prevent Fluoropyrimidine Toxicity. UM Rogel Cancer Center TACR Retreat. February 2, 2024 and Great Lakes Pharmacy Conference March 23, 2024 2023 Precision Health Panel Discussion. U-M Precision Health 5-year Anniversary Symposium, January 11, 2023. 2022 Clinical-Translational Studies to Prevent Severe Fluoropyrimidine Toxicity in DPYD Carriers. Michigan Genomics Initiative 10 Year Anniversary Symposium. October 3, 2022 2021 Evidence Supporting Pre-treatment DPYD Testing. University of Michigan Kemp Cease Heme/Onc Research Conference. January 28, 2021 2018 Prediction of Taxane-induced Peripheral Neuropathy. University of Michigan Hematology Oncology Research Conference, March 15, 2018 2017 Identification of Neuropathy Predictors for Individualized Paclitaxel Treatment. MICHR Studio. May 18, 2017 2016 Discovery of Predictors of Peripheral Neuropathy to Guide Individualized Paclitaxel Treatment. University of Michigan Breast Oncology Program Translational Medicine Forum, September 29, 2016  Discovery of Individualized Predictors of Cancer Treatment Outcomes. University of Michigan Hematology Oncology Research Conference, February 25, 2016  CYP Pharmacogenetics to Predict Breast Cancer Treatment Outcomes. University of Michigan Heme Team, February 18, 2016 2015 Identification of neuropathy predictors for individualized paclitaxel treatment. University of Michigan MICHR CTSA External Advisory Board Meeting October 23, 2015  Personalizing Paclitaxel Treatment in Breast Cancer Patients. University of Michigan CanSORT Project Team Meeting April 28, 2015 2013 A genome-wide association study of docetaxel-induced peripheral neuropathy in CALGB 90401. University of Michigan Hematology/Oncology Research Conference, May 23, 2013  Germline Pharmacogenetics in Cancer: Recognizing the Forgotten Genome. University of Michigan/Hematology/Oncology Research Conference, May 2, 2013  Germline Genetic Predictors of Paclitaxel Efficacy and Toxicity. University of Michigan Translational Breast Cancer Symposium, April 17, 2013  Pharmacogenetic Predictors of Paclitaxel Response and Toxicity in Breast Cancer Patients. Breast Spore Meeting, Jan 22, 2013  Discovery and Validation of Pharmacogenetic Predictors of Taxane-induced Peripheral Neuropathy, Graduate Dissertation Defense, Jan 4, 2013 2012 Discovery and Validation of Pharmacogenetic Markers of Paclitaxel-Induced Peripheral Neuropathy. Gentris Corp, Oct 24, 2012  Pharmacogenetics of Paclitaxel-Induced Neuropathy, Perou Lab Meeting, Sept 27, 2012  Patients Carrying CYP2C8\*3 are at Increased Risk of Paclitaxel-induced Neuropathy, UNC Eshelman School of Pharmacy Graduate Program Retreat, Aug 20, 2012 2011 The Influence of Polymorphisms in Drug Exposure Genes on the Risk of Severe Paclitaxel-induced Neuropathy, Division of Pharmacotherapy and Experimental Therapeutics Seminar, Nov 15, 2011 2010 Genetic Predictors of Taxane Treatment Outcomes, Division of Pharmacotherapy and Experimental Therapeutics Seminar, March 23, 2010 Prior to 2010 Creation of a Murine Mammary Carcinoma Model to Test Metronomic Delivery of a Chemotherapeutic Agent, Ernest Mario School of Pharmacy Honors Program Symposium, April 26, 2007  Synthesis of PTTP Semi-Conducting Organic Layer for a Thin Film Transistor, IGERT Summer Undergraduate Research Fellowship Symposium, Aug 12, 2004 | |
| Teaching and Mentoring | |
| University of Michigan | |
| College of Pharmacy Teaching | |
| 2019-Present  2018-Present  2018-2019  2017-Present  2017-2021  2016-2023  2016-PRESENT  2013-2023  2013-2019 | Topics in Translational Research (CP851)  UM Course Coordinator  Grant Writing I (CP801)  Course Co-Coordinator  Introduction to Precision Health (P217)  Guest Lecturer, 1 unit, Precision Medicine In Oncology  CPTS Seminar (CP850)  Course coordinator  Evidence Based Medicine (P604)  Course Coordinator, responsible for content in 2nd half of semester  Science of Medicine (P200)  Guest lecturer, 3 units: Precision Medicine, Personalized Medicine, and Internet of Health  Clinical and Research Ethics (P312)  Course Coordinator, lecturer (3 units)  Introduction to Clinical Trials (P647)  Co-Course Director, Responsible for Semester-long group project, Lecturer (4 units, 2016-2018)  Pharmacotherapeutics for Primary Care 1 (Nursing P620)  Guest lecturer, 2 units: Pharmacogenomics and Drug Interactions  Introduction to Drug Development (P101)  Guest lecturer, 1 unit: Precision Medicine: Hype or Reality?  Therapeutics Problem Solving (Pharmacy 432/620)  Guest lecturer, 2 units: Drug Interactions and Therapeutic Drug Monitoring  Biopharmaceutics & Pharmacogenomics (Pharmacy 563/718)  Guest lecturer, 3 units: Retrospective PGx Analyses and Prospective PGx Studies (2019-present)  Guest lecturer, 2 units: Germline Testing in Oncology and Race/Sex in PGx (2013-2018) |
| Pharm D Investigation Students: | |
| Class of 2026  2025  2024  2023  2022  2021  2020  2019  2018  2017  2016 | Lia D’Angelo, April Moy, Qinghong Xie  Julieta Bass, Doug Obenrader, Lauren Yates, Brent Zahn, Yerial Jun  Brandon Paulson, Ashley Henderson  Li Chen, Jaeyoung Choi, Mary Hwang  Courtney Van Houzen, Arti Patel, Chloe Koo, Chanel Hsiang  Harsha Guntupalli, Ivy Kim, Christina Weiss, Judith Kim  Colin Finley, Vineet Pradhan, Taylor Coe, Lucas Hamelink, Jung Won Kwon  Kiran Vangipuram, Jackeline Dempsey, Kristin Soreide, Adam Robinson  Andrew Glatz, Emily Krumbach, Emily Han (co-adviser)  Emily Van Wieren, Holly Reed, Andrew Nobani, Lauren Marcath  William Danko, Hugh Nguyen |
| Post-doctoarl fellows: | |
| 2023-Present  2019-2021  2017-2019  2016-2018 | Ciao-Sin (Chelsea) Chen  Faisal Shakeel, Thomas Helland  Lauren Marcath  Amy Pasternak, Yihan Sun (Co-mentor) |
| PhD Students: | |
| 2023-Present  2022-Present  2020-2024  2019-2023  2017-2020 | Ilia Rattsev (John’s Hopkins)  Nam Nguyen  Sidi Wang (UM School of Public Health)  Yuchen Sun  Rotana Radwan (VCU College of Pharmacy)  Ciao-Sin (Chelsea) Chen  Yan-Cheng Chao (UM School of Public Health) |
| BSPS Honors Students: | |
| 2022-2023  2019-2021  2018-2020 | Helen Satsu (Co-mentor)  Yuanhuang (Harry) Chen  Yongzhen Chan |
| MSIPS Master’s Students: | |
| 2022-2023 | Yue Cheng |
| Other Research Mentees | |
| 2024  2022  2021  2021  2017-2021  2019-2020  2019  2017-2018  2016-2018  2014-2015 | Heather Frankel (Boise State Genetic Counseling Master’s Capstone)  Javier Granados II (MICHR Summer Research Program)  Jiawei Chen (MICHR Summer Research Program)  Jung Won Kwon (visiting scholar)  Yan Cheng Chao (SPH PhD Student, dissertation committee)  Heba Izmirli (visiting scholar)  Arti Patel (MICHR Summer Research Program)  Jaeyoung Choi, Liliana Camaj (UROP)  Noemi Garg (BSPS Student)  Alisha Vora (UM Undergraduate Student) |
| University of North carolina | |
| UNC Eshelman School of Pharmacy Teaching | |
| 2012  2011  2010 | Quantitative Methods in Clinical Research (DPET 831)  Guest lecturer, Statistics in Pharmacogenetics Lecture and Recitation Activity  Science and Methods in Drug Development (DPET 841)  Course Development Team  Super Teaching Assistant (DPET 831)  Recitation Developer and Instructor |
| Research mentees | |
| 2012 | Stefanie D Krens, Visiting Scholar, University of Utrecht |
| Service to the University of Michigan College of Pharmacy | |
| 2023-Present  2022-Present  2018-Present  2017-2023  2016-2019  2016-2018  2016-2018  2013-2018  2013-2016  2013-2015 | CPTS PhD Program Graduate Program Director  Co-Chair, Faculty Development Committee  MSIPS Committee  Director of Admissions, CPTS Fellowship and PhD Programs  Co-chair, Oncology Reorganization Committee  Member, Research Foci Committee  Director, CPTS Post-Doctoral Fellowship Seminar Series  Member, Academic Integrity Task Force  Member, PharmD Investigations Committee  Member, Faculty Development Committee  Other: Faculty Mentor for 2 Pharmacy Phamilies, PharmD Patient Counseling Competition Patient, Faculty Auction, PharmD Student Interviews, Dean Candidate Interview Dinner, Volunteer Patient for P1 Laboratory Activity, Pharmacogenomics Working Group (2014-2015), Faculty Chaperone for PharmD Student Smoking Cessation Outreach Project (2014), |
| Service to the University of Michigan | |
| 2022-Present  2020-Present  2018-2022 | Co-Chair Cancer Prevention and Survivorship CRT, Rogel Cancer Center  Faculty Senate Representative  General Counsels Advisory Committee (GCAC), Member |
| Professional Service | |
| Professional Society Memberships | |
| 2022-Present 2020-Present  2015-Present  2014-Present  2013-Present  2013-2015  2012-Present | MASCC *DPYD* Working Group Co-Chair  MASCC Neurological Complications Working Group, Vice Chair (2022-2025), Biomarkers co-lead (2020-2022)  Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Study Design Task Force Vice Chair and Clinical Subcommittee Chair, Peripheral Nerve Society (PNS)  American Society of Clinical Pharmacology and Therapeutics (ASCPT), PGx Community Programming Steering Committee Member (2017) and Chair (2018). PGx Community Vice Chair (2019), chair (2020) and past-chair (2021)  Pharmacogenomics Research Network (PGRN) Affiliate Member, Founding member (2020), Onc SIG Enhancing PGx in Oncology Organizations (EPO) Subcommittee Chair  SWOG (Inter-group) Drug Interactions Task Force Committee Chair  Southwest Oncology Group (SWOG), Pharmaceutical Sciences Committee, Drug Information Subcommittee, Breast Cancer Translational Medicine Committee, Pharmacist Liaison to Cancer Control & Lung Committees (2014-2016)  Pharmacogenomics Knowledge Bank (PharmGKB)  Clinical Pharmacogenetics Implementation Consortium (CPIC), CYP2D6 Genotype-to-Phenotype Working Group Member  American Society for Clinical Oncology (ASCO)  American College of Clinical Pharmacy (ACCP)  Alliance for Clinical Trials in Oncology, Pharmacogenomics and Population Pharmacokinetics (PPP) Committee Cadre Member |
| Workshops at professional Meetings | |
| ASCPT 2018 | Substrate-Dependent Polymorphic Effects in CYP-Mediated Drug Metabolism and Challenges for Pharmacogenetic Implementation, Session Chair. March 24, 1:15-2:45, ASCPT Annual Meeting |
| Editorial and Referee Service | |
| 2020-2021  2019-Present 2015-2019 | Guest Editor, Special Issue Germline Pharmacogenetics of Cancer Treatment, Cancers  Editorial Board Member, Pharmacogenomics  Editorial Board Member, Physiological Genomics |
| Ad hoc Journal referee (alphabetical): AAPS Journal  Acta Biochimica Polonica  Acta Oncologica  African Health Sciences  Annals of Oncology  Annals of Pharmacotherapy  BioMed Research International  BMC Cancer  BMC Medical Genomics  BMC Women’s Health  BMJ Supportive & Palliative Care  Brazilian Journal of Pharmaceutical Sciences  Breast Cancer Research and Treatment  British Journal of Cancer  British Journal of Clinical Pharmacology  Cancer  Cancer Chemotherapy and Pharmacology  Cancer Control: Journal of the Moffitt Cancer Center  Cancer Epidemiology, Biomarkers, and Prevention  Cancer Management and Research  Cancer Medicine  Cancer Treatment Reviews  Cancers  Clinical and Translational Science  Clinical Breast Cancer  Clinical Cancer Research  Clinical Nutrition ESPEN  Clinical Pharmacokinetics  Clinical Pharmacology & Therapeutics  Clinical Therapeutics  Current Drug Safety  Dose-Response  Drug Healthcare and Patient Safety  ESMO Open  European Journal of Neurology  Expert Opinion On Drug Metabolism & Toxicology  Expert Review of Molecular Diagnostics  Expert Review of Neurotherapeutics  Expert Review of Precision Medicine and Drug Development  Frontiers in Genetics  Frontiers in Oncology  Frontiers in Pharmacology  Genes  Genetics in Medicine  Genome Medicine  Genomics  Heliyon  High Throughput  International Journal of Molecular Sciences  JAMA Network Open  Journal of Cancer Survivorship  Journal of Chemotherapy  Journal of Clinical Investigation  Journal of Clinical Medicine  Journal of Clinical Oncology  Journal of National Cancer Institute  Journal of Neurological Sciences  Journal of Oncology Pharmacy Practice  Journal of the Peripheral Nervous System  Journal of Pain and Symptom Management  Journal of Personalized Medicine  Journal of Proteome Research  JCO Precision Oncology  Medicina  Molecular Cancer Therapeutics  Molecular Diagnosis and Therapy  Molecules  Neuro-Oncology Practice  Oncotarget  Oncotargets and Therapy  Personalized Medicine  Pharmaceutical Research  Pharmacogenetics and Genomics  Pharmacogenomics  Pharmacogenomics and Personalized Medicine  Pharmacology Research & Perspectives  Pharmacotherapy  PLOS One  Scientific Reports  Supportive Care in Cancer  The Annals of Pharmacotherapy  The Breast  The Oncologist  The Pharmacogenomics Journal  Toxicology Research  Translational Cancer Research  Trends in Pharmacological Sciences Grant Review Panel member: American Cancer Society Cancer Detection and Progression  National Cancer Institute XNDA Ad hoc Grant Review: American Cancer Society  American Foundation of Pharmaceutical Education  Cancer Research United Kingdom (CRUK)  Congressionally Directed Medical Research Program (CDMRP)  KWF Kankerbestrijding – Dutch Cancer Society (DCS)  MICHR Pilot Grant Program  National Cancer Institute  Welcome Trust Ad hoc abstract Review: American Society of Clinical Pharmacology and Therapeutics 2017-2021 Annual Meeting  Association for Clinical and Translational Science 2018 Annual Meeting  Awards and Honors | |
| 2024  2015  2013  2012  2011  2010  2009  2008  2007  2006  2005  2004 | STRIPE Double Helix Award  MICHR K Mentored Clinical Scientist Career Development Award  Graduate Education Advancement Board Impact Award  American Association of Cancer Research Scholar-In-Training  Cancer Institute of New Jersey Young Philanthropist Award  AFPE Pre-Doctoral Fellowship Competitive Renewal  AFPE Pre-Doctoral Fellowship  Excellence in Teaching/Instruction Assistance Award  Ernest Mario School of Pharmacy Honors Program Graduate  Cell Biology Achievement Award  Rho Chi-AFPE First Year Graduate Scholarship  Martin Daffner Endowed Scholarship  New Jersey Center for Biomaterials Summer Research Fellowship  John & Josephine Calasibetta Scholarship  Rho Chi National Pharmacy Honor Society Inductee  Novarits-AFPE Gateway to Research Scholarship  Martin Daffner Endowed Scholarship  Pharmacy Alumni Association Scholarship  “Knight In Shining Armor” Award for Student Involvement  Eric D. Siefert Scholarship  IGERT-Summer Undergraduate Research Fellowship |